User Image Cart Icon 0 Search Image

Cdk5

  1. The role of CDK5 /P25 formation/inhibition in neurodegeneration.
  2. A decade of CDK5
  3. CDK5 deregulation in the pathogenesis of Alzheimer’s disease
  4. Conversion of p35 to p25 deregulates CDK5 activity and promotes neurodegeneration
  5. The CDK5 /p35 kinase is essential for neurite outgrowth during neuronal differentiation.
  6. The p35/CDK5 kinase is a neuron-specific Rac effector that inhibits Pak1 activity
  7. CDK5 -mediated inhibition of the protective effects of transcription factor MEF2 in neurotoxicity-induced apoptosis
  8. p35, the neuronal-specific activator of cyclin-dependent kinase 5 (CDK5 ) is degraded by the ubiquitin-proteasome pathway
  9. Cables links CDK5 and c-Abl and facilitates CDK5 tyrosine phosphorylation, kinase upregulation, and neurite outgrowth
  10. Aberrant CDK5 activation by p25 triggers pathological events leading to neurodegeneration and neurofibrillary tangles
  11. Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPARγ by CDK5
  12. CDK5 regulates EphA4-mediated dendritic spine retraction through an ephexin1-dependent mechanism
  13. Effects of chronic exposure to cocaine are regulated by the neuronal protein CDK5
  14. Phosphorylation of DARPP-32 by CDK5 modulates dopamine signalling in neurons
  15. CDK5 serves as a major control point in neurotransmitter release
  16. Mice lacking p35, a neuronal specific activator of CDK5 , display cortical lamination defects, seizures, and adult lethality
  17. Indirubins Inhibit Glycogen Synthase Kinase-3β and CDK5 /P25, Two Protein Kinases Involved in Abnormal Tau Phosphorylation in Alzheimer’s Disease: A …
  18. Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin‐dependent kinases cdc2, cdk2 and CDK5
  19. Abnormal Alzheimer‐like phosphorylation of tau‐protein by cyclin‐dependent kinases cdk2 and CDK5
  20. CDK5 is a key factor in tau aggregation and tangle formation in vivo
  21. Fyn and CDK5 mediate semaphorin-3A signaling, which is involved in regulation of dendrite orientation in cerebral cortex
  22. Semaphorin3A signalling is mediated via sequential CDK5 and GSK3β phosphorylation of CRMP2: implication of common phosphorylating mechanism underlying …
  23. Hyperphosphorylated tau and neurofilament and cytoskeletal disruptions in mice overexpressing human p25, an activator of CDK5
  24. Structure and regulation of the CDK5 -p25nck5a complex
  25. Deregulation of CDK5 in a mouse model of ALS: toxicity alleviated by perikaryal neurofilament inclusions
  26. CDK5 /p35 regulates neurotransmitter release through phosphorylation and downregulation of P/Q-type voltage-dependent calcium channel activity
  27. Inhibition of tau phosphorylating protein kinase CDK5 prevents β-amyloid-induced neuronal death
  28. A Jekyll and Hyde kinase: roles for CDK5 in brain development and disease
  29. An isoform of the neuronal cyclin-dependent kinase 5 (CDK5 ) activator
  30. Silencing of CDK5 reduces neurofibrillary tangles in transgenic alzheimer’s mice
  31. NUDEL is a novel CDK5 substrate that associates with LIS1 and cytoplasmic dynein
  32. … specificities of protein Ser/Thr kinases: primary sequence preference of casein kinases I and II, NIMA, phosphorylase kinase, calmodulin-dependent kinase II, CDK5 …
  33. Accumulation of cyclin-dependent kinase 5 (CDK5 ) in neurons with early stages of Alzheimer’s disease neurofibrillary degeneration
  34. CDK5 is essential for synaptic vesicle endocytosis
  35. CDK5 : a multifaceted kinase in neurodegenerative diseases
  36. CDK5 activation induces hippocampal CA1 cell death by directly phosphorylating NMDA receptors
  37. CDK5 phosphorylation of doublecortin ser297 regulates its effect on neuronal migration
  38. The protein kinase CDK5 : structural aspects, roles in neurogenesis and involvement in Alzheimer’s pathology
  39. S-Nitrosylation activates CDK5 and contributes to synaptic spine loss induced by β-amyloid peptide
  40. Serine 732 phosphorylation of FAK by CDK5 is important for microtubule organization, nuclear movement, and neuronal migration
  41. CDK5 regulates the organization of Nestin and its association with p35
  42. CDK5 is involved in BDNF-stimulated dendritic growth in hippocampal neurons
  43. Antidiabetic actions of a non-agonist PPARγ ligand blocking CDK5 -mediated phosphorylation
  44. CDK5 -dependent regulation of glucose-stimulated insulin secretion
  45. Transcriptional regulation of β-secretase by p25/CDK5 leads to enhanced amyloidogenic processing
  46. Mechanism of CDK5 /p25 binding by CDK inhibitors
  47. Inhibiting the cyclin-dependent kinase CDK5 blocks pancreatic cancer formation and progression through the suppression of Ras-Ral signaling
  48. CDK5 is essential for TGF-β1-induced epithelial-mesenchymal transition and breast cancer progression
  49. A CDK5 inhibitory peptide reduces tau hyperphosphorylation and apoptosis in neurons
  50. p39 activates CDK5 in neurons, and is associated with the actin cytoskeleton
  51. ERK induces p35, a neuron-specific activator of CDK5 , through induction of Egr1
  52. Interleukin-6 induces Alzheimer-type phosphorylation of tau protein by deregulating the CDK5 /p35 pathway
  53. CDK5 phosphorylation of huntingtin reduces its cleavage by caspases: implications for mutant huntingtin toxicity
  54. An unusual member of the Cdk family: CDK5
  55. CDK5 is involved in neuregulin-induced AChR expression at the neuromuscular junction
  56. Deregulation of HDAC1 by p25/CDK5 in neurotoxicity
  57. A model of the complex between cyclin-dependent kinase 5 and the activation domain of neuronal CDK5 activator
  58. Role of CDK5 -mediated phosphorylation of Prx2 in MPTP toxicity and Parkinson’s disease
  59. Involvement of aberrant glycosylation in phosphorylation of tau by CDK5 and GSK-3β
  60. Synaptic roles of CDK5 : implications in higher cognitive functions and neurodegenerative diseases
  61. A nestin scaffold links CDK5 /p35 signaling to oxidant‐induced cell death
  62. CDK5 -mediated phosphorylation of endophilin B1 is required for induced autophagy in models of Parkinson’s disease
  63. Regulation of N-cadherin-mediated adhesion by the p35–CDK5 kinase
  64. CDK5 phosphorylates and stabilizes p27kip1 contributing to actin organization and cortical neuronal migration
  65. Site-specific phosphorylation of synapsin I by mitogen-activated protein kinase and CDK5 and its effects on physiological functions
  66. A novel CDK5 ‐dependent pathway for regulating GSK3 activity and kinesin‐driven motility in neurons
  67. Deregulated CDK5 promotes oxidative stress and mitochondrial dysfunction
  68. Phosphorylation of MEK1 by CDK5 /p35 down-regulates the mitogen-activated protein kinase pathway
  69. Deregulated CDK5 activity is involved in inducing Alzheimer’s disease
  70. A survey of CDK5 activator p35 and p25 levels in Alzheimer’s disease brains
  71. Neurotransmitter acetylcholine negatively regulates neuromuscular synapse formation by a CDK5 -dependent mechanism
  72. Calpain-regulated p35/CDK5 plays a central role in dopaminergic neuron death through modulation of the transcription factor myocyte enhancer factor 2
  73. CDK5 regulates STAT3 activation and cell proliferation in medullary thyroid carcinoma cells
  74. A CDK5 –p35 stable complex is involved in the β-amyloid-induced deregulation of CDK5 activity in hippocampal neurons
  75. CDK5 phosphorylates p53 and regulates its activity
  76. A cdc2-related kinase PSSALRE/CDK5 is homologous with the 30 kDa subunit of tau protein kinase II, a proline-directed protein kinase associated with microtubule
  77. CDK5 is essential for adult hippocampal neurogenesis
  78. The role of CDK5 in neuroendocrine thyroid cancer
  79. CDK5 regulates the phosphorylation of tyrosine 1472 NR2B and the surface expression of NMDA receptors
  80. Nuclear localization of CDK5 is a key determinant in the postmitotic state of neurons
  81. CDK5 -mediated regulation of the PIKE-A-Akt pathway and glioblastoma cell invasion
  82. CDK5 phosphorylation of WAVE2 regulates oligodendrocyte precursor cell migration through nonreceptor tyrosine kinase Fyn
  83. Deregulation of CDK5 , hyperphosphorylation, and cytoskeletal pathology in the Niemann–Pick type C murine model
  84. Role of protein phosphatase-2A and-1 in the regulation of GSK-3, CDK5 and cdc2 and the phosphorylation of tau in rat forebrain
  85. CDK5 is required for multipolar-to-bipolar transition during radial neuronal migration and proper dendrite development of pyramidal neurons in the cerebral cortex
  86. CDK5 behind the wheel: a role in trafficking and transport?
  87. Evidence for the participation of the neuron-specific CDK5 activator P35 during laminin-enhanced axonal growth
  88. Cophosphorylation of amphiphysin I and dynamin I by CDK5 regulates clathrin-mediated endocytosis of synaptic vesicles
  89. Phosphorylation of Pak1 by the p35/CDK5 kinase affects neuronal morphology
  90. Divergent roles of GSK3 and CDK5 in APP processing
  91. Potentiation of GSK-3-catalyzed Alzheimer-like phosphorylation of human tau by CDK5
  92. Critical role of CDK5 and Polo-like kinase 2 in homeostatic synaptic plasticity during elevated activity
  93. Truncation of CDK5 activator p35 induces intensive phosphorylation of Ser202/Thr205 of human tau
  94. A hippocampal CDK5 pathway regulates extinction of contextual fear
  95. Region‐specific expression of cyclin‐dependent kinase 5 (CDK5 ) and its activators, p35 and p39, in the developing and adult rat central nervous system
  96. CDK5 : multitasking between physiological and pathological conditions
  97. Phosphorylation of ATM by CDK5 mediates DNA damage signalling and regulates neuronal death
  98. Talin phosphorylation by CDK5 regulates Smurf1-mediated talin head ubiquitylation and cell migration
  99. CDK5 promotes synaptogenesis by regulating the subcellular distribution of the MAGUK family member CASK
  100. Phosphorylation of human tau protein by microtubule‐associated kinases: GSK3β and CDK5 are key participants
  101. Extraneuronal activities and regulatory mechanisms of the atypical cyclin-dependent kinase CDK5
  102. The proapoptotic function of Noxa in human leukemia cells is regulated by the kinase CDK5 and by glucose
  103. Regulation of amyloid precursor protein (APP) phosphorylation and processing by p35/CDK5 and p25/CDK5
  104. CDK5 is involved in NFT-like tauopathy induced by transient cerebral ischemia in female rats
  105. CDK5 modulates cocaine reward, motivation, and striatal neuron excitability
  106. Roscovitine regulates invasive breast cancer cell (MDA-MB231) proliferation and survival through cell cycle regulatory protein CDK5
  107. The cyclin-dependent kinase CDK5 controls multiple aspects of axon patterning in vivo
  108. Stabilization and activation of p53 induced by CDK5 contributes to neuronal cell death
  109. Achaete-scute homologue-1 (ASH1) stimulates migration of lung cancer cells through CDK5 /p35 pathway
  110. PKA modulates GSK-3β-and CDK5 -catalyzed phosphorylation of tau in site-and kinase-specific manners
  111. A peptide derived from cyclin‐dependent kinase activator (p35) specifically inhibits CDK5 activity and phosphorylation of tau protein in transfected cells
  112. Glutathione‐S‐transferase P1 is a critical regulator of CDK5 kinase activity
  113. Specific inhibition of p25/CDK5 activity by the CDK5 inhibitory peptide reduces neurodegeneration in vivo
  114. Processing of CDK5 activator p35 to its truncated form (p25) by calpain in acutely injured neuronal cells
  115. CDK5 regulates accurate maturation of newborn granule cells in the adult hippocampus
  116. Involvement of CDK5 /p25 in digoxin-triggered prostate cancer cell apoptosis
  117. A truncated peptide from p35, a CDK5 activator, prevents Alzheimer’s disease phenotypes in model mice
  118. Neurodegeneration in an Aβ‐induced model of Alzheimer’s disease: the role of CDK5
  119. Essential role of cytoplasmic CDK5 and Prx2 in multiple ischemic injury models, in vivo
  120. RNAi screen of the druggable genome identifies modulators of proteasome inhibitor sensitivity in myeloma including CDK5
  121. A 24-residue peptide (p5), derived from p35, the CDK5 neuronal activator, specifically inhibits CDK5 -p25 hyperactivity and tau hyperphosphorylation
  122. Dissociation of tau toxicity and phosphorylation: role of GSK-3β, MARK and CDK5 in a Drosophila model
  123. Inhibition of CDK5 is protective in necrotic and apoptotic paradigms of neuronal cell death and prevents mitochondrial dysfunction
  124. Cyclin I activates CDK5 and regulates expression of Bcl-2 and Bcl-XL in postmitotic mouse cells
  125. Identification of functional domains in the neuronal CDK5 activator protein
  126. AβPP induces CDK5 -dependent tau hyperphosphorylation in transgenic mice Tg2576
  127. Migration defects of CDK5 −/− neurons in the developing cerebellum is cell autonomous
  128. TrkB phosphorylation by CDK5 is required for activity-dependent structural plasticity and spatial memory
  129. Cloning of three novel neuronal CDK5 activator binding proteins
  130. Chronic copper exposure exacerbates both amyloid and tau pathology and selectively dysregulates CDK5 in a mouse model of AD
  131. MAP1B phosphorylation is differentially regulated by CDK5 /p35, CDK5 /p25, and JNK
  132. Tau phosphorylation by CDK5 and Fyn in response to amyloid peptide Aβ 25–35: Involvement of lipid rafts
  133. The regulation of cyclin-dependent kinase 5 activity through the metabolism of p35 or p39 CDK5 activator
  134. CDK5 , a therapeutic target for Alzheimer’s disease?
  135. Decreased cyclin-dependent kinase 5 (CDK5 ) activity is accompanied by redistribution of CDK5 and cytoskeletal proteins and increased cytoskeletal protein …
  136. Identification of the N‐terminal functional domains of CDK5 by molecular truncation and computer modeling
  137. Deregulated CDK5 triggers aberrant activation of cell cycle kinases and phosphatases inducing neuronal death
  138. c-Abl tyrosine kinase modulates tau pathology and CDK5 phosphorylation in AD transgenic mice
  139. Cyclin E constrains CDK5 activity to regulate synaptic plasticity and memory formation
  140. Crosstalk between CDK5 and GSK3β: Implications for Alzheimer’s disease
  141. Cyclin dependent kinase 5, CDK5 , is a positive regulator of myogenesis in mouse C2 cells
  142. Recent advances in understanding the roles of CDK5 in synaptic plasticity
  143. Making a neuron: CDK5 in embryonic and adult neurogenesis
  144. Delayed Treatment with Systemic (S)-Roscovitine Provides Neuroprotection and Inhibits In Vivo CDK5 Activity Increase in Animal Stroke Models
  145. CDK5 suppresses the neuronal cell cycle by disrupting the E2F1–DP1 complex
  146. Regulation of DARPP‐32 dephosphorylation at PKA‐and CDK5 ‐sites by NMDA and AMPA receptors: distinct roles of calcineurin and protein phosphatase‐2A
  147. Cyclin‐dependent protein kinase 5 (CDK5 ) and the regulation of neurofilament metabolism
  148. Mice lacking phosphatase PP2A subunit PR61/B’δ (Ppp2r5d) develop spatially restricted tauopathy by deregulation of CDK5 and GSK3β
  149. The role of the CDK5 –p35 kinase in neuronal development
  150. Neuronal cyclin-dependent kinase 5: role in nervous system function and its specific inhibition by the CDK5 inhibitory peptide
  151. CDK5 phosphorylates Cdh1 and modulates cyclin B1 stability in excitotoxicity
  152. Identification of the 23 kDa subunit of tau protein kinase II as a putative activator of CDK5 in bovine brain
  153. Enterovirus 71 triggering of neuronal apoptosis through activation of Abl‐CDK5 signalling
  154. Cyclin‐dependent kinase 5 (CDK5 ) activation requires interaction with three domains of p35
  155. Control of cyclin‐dependent kinase 5 (CDK5 ) activity by glutamatergic regulation of p35 stability
  156. CDK5 -mediated phosphorylation of CRMP-2 enhances its interaction with CaV2. 2
  157. Going out of the brain: non-nervous system physiological and pathological functions of CDK5
  158. Activation of cyclin-dependent kinase 5 (CDK5 ) in primary sensory and dorsal horn neurons by peripheral inflammation contributes to heat hyperalgesia
  159. CDK5 acts as a mediator of neuronal cell cycle re-entry triggered by amyloid-β and prion peptides
  160. S-nitrosylation of cyclin-dependent kinase 5 (CDK5 ) regulates its kinase activity and dendrite growth during neuronal development
  161. Cellular senescence requires CDK5 repression of Rac1 activity
  162. Analysis of the expression, distribution and function of cyclin dependent kinase 5 (CDK5 ) in developing cerebellar macroneurons
  163. A CDK5 -dependent switch regulates Lis1/Ndel1/dynein-driven organelle transport in adult axons
  164. p25/CDK5 -mediated retinoblastoma phosphorylation is an early event in neuronal cell death
  165. Expression of CDK5 /p35 in resected patients with non-small cell lung cancer: relation to prognosis
  166. Modulation of aberrant CDK5 signaling rescues impaired neurogenesis in models of Alzheimer’s disease
  167. CDK5 : one of the links between senile plaques and neurofibrillary tangles?
  168. CDK5 /p25-induced cytosolic PLA2-mediated lysophosphatidylcholine production regulates neuroinflammation and triggers neurodegeneration
  169. Balance of calcineurin Aα and CDK5 activities sets release probability at nerve terminals
  170. Colocalization and fluorescence resonance energy transfer between CDK5 and AT8 suggests a close association in pre-neurofibrillary tangles and neurofibrillary …
  171. CDK5 is required for memory function and hippocampal plasticity via the cAMP signaling pathway
  172. Amphiphysin 1 binds the cyclin-dependent kinase (cdk) 5 regulatory subunit p35 and is phosphorylated by CDK5 and cdc2
  173. p35/CDK5 binds and phosphorylates β‐catenin and regulates β‐catenin/presenilin‐1 interaction
  174. CDK5 Modulation of mitogen-activated protein kinase signaling regulates neuronal survival
  175. Spatial learning impairment, enhanced CDK5 /p35 activity, and downregulation of NMDA receptor expression in transgenic mice expressing tau-tubulin kinase 1
  176. CDK5 : mediator of neuronal death and survival
  177. The brain-specific activator p35 allows CDK5 to escape inhibition by p27Kip1 in neurons.
  178. The role of CDK5 -mediated apurinic/apyrimidinic endonuclease 1 phosphorylation in neuronal death
  179. Angiostatin‐induced inhibition of endothelial cell proliferation/apoptosis is associated with the down‐regulation of cell cycle regulatory protein CDK5
  180. p35/CDK5 pathway mediates soluble amyloid‐β peptide‐induced tau phosphorylation in vitro
  181. Myocardin-related transcription factors regulate the CDK5 /Pctaire1 kinase cascade to control neurite outgrowth, neuronal migration and brain development
  182. Drebrin contains a cryptic F-actin–bundling activity regulated by CDK5 phosphorylation
  183. Inhibition of CDK5 in the nucleus accumbens enhances the locomotor-activating and incentive-motivational effects of cocaine
  184. Mitotic-like tau phosphorylation by p25-CDK5 kinase complex
  185. CDK5 regulates axonal transport and phosphorylation of neurofilaments in cultured neurons
  186. Targeting CDK5 activity in neuronal degeneration and regeneration
  187. CDK5 : a new player in pain signaling
  188. Disruption of CDK5 -associated phosphorylation of residue threonine-161 of the δ-opioid receptor: impaired receptor function and attenuated morphine antinociceptive …
  189. Expression of CDK5 (PSSALRE kinase), a neural cdc2-related protein kinase, in the mature and developing mouse central and peripheral nervous systems
  190. CDK5 regulates differentiation of oligodendrocyte precursor cells through the direct phosphorylation of paxillin
  191. CDK5 and MEKK1 mediate pro-apoptotic signalling following endoplasmic reticulum stress in an autosomal dominant retinitis pigmentosa model
  192. Level of CDK5 expression predicts the survival of relapsed multiple myeloma patients
  193. The CDK5 kinase regulates the STAT3 transcription factor to prevent DNA damage upon topoisomerase I inhibition
  194. Activation of the calpain/CDK5 /p25 pathway in the girus cinguli in Parkinson’s disease
  195. Phosphorylation of the high molecular weight neurofilament protein (NF-H) by CDK5 and p35
  196. Nuclear envelope dispersion triggered by deregulated CDK5 precedes neuronal death
  197. Suppression of calpain-dependent cleavage of the CDK5 activator p35 to p25 by site-specific phosphorylation
  198. Cyclin-dependent kinase 5 (CDK5 ) activation domain of neuronal CDK5 activator: Evidence of the existence of cyclin fold in neuronal CDK5 a activator
  199. Interaction of Cyclin-dependent Kinase 5 (CDK5 ) and Neuronal CDK5 Activator in Bovine Brain (∗)
  200. Recent evidence regarding a role for CDK5 dysregulation in Alzheimer’s disease
  201. CDK5 is a major regulator of p38 cascade: relevance to neurotoxicity in Alzheimer’s disease
  202. Defining CDK5 ligand chemical space with small molecule inhibitors of tau phosphorylation
  203. Kainate induces AKT, ERK and CDK5 /GSK3β pathway deregulation, phosphorylates tau protein in mouse hippocampus
  204. Evaluation and comparison of 3D-QSAR CoMSIA models for CDK1, CDK5 , and GSK-3 inhibition by paullones
  205. Target-derived GFRα1 as an attractive guidance signal for developing sensory and sympathetic axons via activation of CDK5
  206. The atypical kinase CDK5 is activated by insulin, regulates the association between GLUT4 and E-Syt1, and modulates glucose transport in 3T3-L1 adipocytes
  207. The protective effects of tanshinone IIA on neurotoxicity induced by β-amyloid protein through calpain and the p35/CDK5 pathway in primary cortical neurons
  208. Potential roles of CDK5 /p35 and tau protein in hippocampal mossy fiber sprouting in the PTZ kindling model.
  209. Cyclin-dependent kinase 5 (CDK5 ) and neuron-specific CDK5 activators
  210. CDK5 protein inhibition and Aβ42 increase BACE1 protein level in primary neurons by a post-transcriptional mechanism: implications of CDK5 as a …
  211. Inhibition of the CDK5 /p25 fragment formation may explain the antiapoptotic effects of melatonin in an experimental model of Parkinson’s disease
  212. The CDK5 repressor CDK5 RAP1 is a methylthiotransferase acting on nuclear and mitochondrial RNA
  213. GDNF hyperalgesia is mediated by PLCγ, MAPK/ERK, PI3K, CDK5 and Src family kinase signaling and dependent on the IB4‐binding protein versican
  214. Oxidative stress promotes τ dephosphorylation in neuronal cells: the roles of CDK5 and PP1
  215. The CDK5 -p35 kinase associates with the Golgi apparatus and regulates membrane traffic
  216. Schizophrenia is associated with dysregulation of a CDK5 activator that regulates synaptic protein expression and cognition
  217. Abl deregulates CDK5 kinase activity and subcellular localization in Drosophila neurodegeneration
  218. CDK5 -mediated phosphorylation of c-Myc on Ser-62 is essential in transcriptional activation of cyclin B1 by cyclin G1
  219. LMTK1/AATYK1 is a novel regulator of axonal outgrowth that acts via Rab11 in a CDK5 -dependent manner
  220. Identification of a neuronal CDK5 activator-binding protein as CDK5 inhibitor
  221. Phosphorylation of p35 and p39 by CDK5 determines the subcellular location of the holokinase in a phosphorylation-site-specific manner
  222. CDK5 -mediated phosphorylation of Axin directs axon formation during cerebral cortex development
  223. The serotonin receptor 7 promotes neurite outgrowth via ERK and CDK5 signaling pathways
  224. Increased CDK5 expression in HIV encephalitis contributes to neurodegeneration via tau phosphorylation and is reversed with Roscovitine
  225. No difference in kinetics of tau or histone phosphorylation by CDK5 /p25 versus CDK5 /p35 in vitro
  226. Identification of nuclear import mechanisms for the neuronal CDK5 activator
  227. Overexpression of a Novel Activator of PAK4, the CDK5 Kinase–Associated Protein CDK5 RAP3, Promotes Hepatocellular Carcinoma MetastasisCDK5 RAP3 Activates …
  228. Sustained cell polarity and virulence in the phytopathogenic fungus Ustilago maydis depends on an essential cyclin-dependent kinase from the CDK5 /Pho85 family
  229. Activity-dependent phosphorylation of neuronal Kv2. 1 potassium channels by CDK5
  230. L6 myoblast differentiation is modulated by CDK5 via the PI3K–AKT–p70S6K signaling pathway
  231. Increased ezrin expression and activation by CDK5 coincident with acquisition of the senescent phenotype
  232. Elevation of p-NR2AS1232 by CDK5 /p35 contributes to retinal ganglion cell apoptosis in a rat experimental glaucoma model
  233. Class 3 semaphorin mediates dendrite growth in adult newborn neurons through CDK5 /FAK pathway
  234. Identification of tyrosine hydroxylase as a physiological substrate for CDK5
  235. Quantitative measurement of in vivo phosphorylation states of CDK5 activator p35 by Phos-tag SDS-PAGE
  236. Role of CDK5 in neuronal signaling, plasticity, and drug abuse
  237. Mammalian CDK5 is a functional homologue of the budding yeast Pho85 cyclin-dependent protein kinase
  238. The role of CDK5 and GSK3B kinases in hyperphosphorylation of microtubule associated protein tau (MAPT) in Alzheimer’s disease
  239. The expression of CDK5 , p35, p39, and CDK5 kinase activity in developing, adult, and aged rat brains
  240. CDK5 nuclear localization is p27-dependent in nerve cells: implications for cell cycle suppression and caspase-3 activation
  241. … of neuronal Cdc2-like kinase from bacteria-expressed CDK5 and an active fragment of the brain-specific activator: Kinase activation in the absence of CDK5 …
  242. Phosphorylation of protein phosphatase inhibitor-1 by CDK5
  243. Involvement of calpain/p35-p25/CDK5 /NMDAR signaling pathway in glutamate-induced neurotoxicity in cultured rat retinal neurons
  244. CDK5 activator-binding protein C53 regulates apoptosis induced by genotoxic stress via modulating the G2/M DNA damage checkpoint
  245. Role of CDK5 in drug abuse and plasticity
  246. Isomerase Pin1 stimulates dephosphorylation of tau protein at cyclin-dependent kinase (CDK5 )-dependent Alzheimer phosphorylation sites
  247. CDK5 regulates the size of an axon initial segment-like compartment in mushroom body neurons of the Drosophila central brain
  248. Enhanced CDK5 activity and p35 translocation in the ventral striatum of acute and chronic methamphetamine-treated rats
  249. Basolateral amygdala CDK5 activity mediates consolidation and reconsolidation of memories for cocaine cues
  250. Transforming growth factor-β1 regulates CDK5 activity in primary sensory neurons
  251. Perinatal abrogation of CDK5 expression in brain results in neuronal migration defects
  252. CDK5 , the multifunctional surveyor
  253. Suppression of mutant Huntingtin aggregate formation by CDK5 /p35 through the effect on microtubule stability
  254. Relative resistance of CDK5 -phosphorylated CRMP2 to dephosphorylation
  255. Nestin as a regulator of CDK5 in differentiating myoblasts
  256. Role of CDK5 in the pathogenesis of Alzheimer’s disease
  257. Brain levels of CDK5 activator p25 are not increased in Alzheimer’s or other neurodegenerative diseases with neurofibrillary tangles
  258. The protein SET binds the neuronal CDK5 activator p35 nck5a and modulates CDK5 /p35 nck5a activity
  259. Characterization of the in vitro phosphorylation of human tau by tau protein kinase II (CDK5 /p20) using mass spectrometry
  260. Potent inhibitors of CDK5 derived from roscovitine: Synthesis, biological evaluation and molecular modelling
  261. CDK5 and MAPK are associated with complexes of cytoskeletal proteins in rat brain
  262. Cyclin-dependent kinase 5 (CDK5 ) and neuronal cell death
  263. Phosphorylation of spinophilin by ERK and cyclin-dependent PK 5 (CDK5 )
  264. A novel, extraneuronal role for cyclin-dependent protein kinase 5 (CDK5 ): modulation of cAMP-induced apoptosis in rat leukemia cells
  265. Cyclin E is expressed in neurons and forms complexes with CDK5
  266. Increased CDK5 /p35 activity in the dentate gyrus mediates depressive-like behaviour in rats
  267. Phosphoregulation of the RNA-binding protein Hu antigen R (HuR) by CDK5 affects centrosome function
  268. Synaptic NMDA receptor stimulation activates PP1 by inhibiting its phosphorylation by CDK5
  269. ROCK inhibition prevents tau hyperphosphorylation and p25/CDK5 increase after global cerebral ischemia.
  270. Coexpression of human CDK5 and its activator p35 with human protein tau in neurons in brain of triple transgenic mice
  271. AKT and CDK5 /p35 mediate brain-derived neurotrophic factor induction of DARPP-32 in medium size spiny neurons in vitro
  272. Cyclin I-CDK5 governs survival in post-mitotic cells
  273. Evidence for CDK5 as a major activity phosphorylating tau protein in porcine brain extract
  274. Alternative roles for CDK5 in learning and synaptic plasticity
  275. Pctaire1 interacts with p35 and is a novel substrate for CDK5 /p35
  276. S-nitrosylation of CDK5 : potential implications in amyloid-β-related neurotoxicity in Alzheimer disease
  277. Synaptic localization of p39, a neuronal activator of CDK5
  278. … -induced analgesic tolerance, locomotor sensitization and physical dependence do not require modification of mu opioid receptor, CDK5 and adenylate cyclase activity
  279. Involvement of calpain and p25 of CDK5 pathway in ginsenoside Rb1’s attenuation of β-amyloid peptide25–35-induced tau hyperphosphorylation in cortical neurons
  280. Nestin protects mouse podocytes against high glucose‐induced apoptosis by a CDK5 ‐dependent mechanism
  281. Phosphorylation of the tubulin‐binding protein, stathmin, by CDK5 and MAP kinases in the brain
  282. p10, the N-terminal domain of p35, protects against CDK5 /p25-induced neurotoxicity
  283. CDK5 regulates cell adhesion and migration in corneal epithelial cells
  284. Twice switched at birth: cell cycle-independent roles of the “neuron-specific” cyclin-dependent kinase 5 (CDK5 ) in non-neuronal cells
  285. CDK5 /p25nck5a interaction with synaptic proteins in bovine brain
  286. Impaired neurogenesis and neurite outgrowth in an HIV-gp120 transgenic model is reversed by exercise via BDNF production and CDK5 regulation
  287. Charcot–Marie–Tooth causing HSPB1 mutations increase CDK5 -mediated phosphorylation of neurofilaments
  288. The role of CDK5 in cognition and neuropsychiatric and neurological pathology
  289. CDK5 as a drug target for the treatment of Alzheimer’s disease
  290. Phosphorylation of gephyrin in hippocampal neurons by cyclin-dependent kinase CDK5 at Ser-270 is dependent on collybistin
  291. … binding and clustering of human Tau-4R and Tau-P301L proteins isolated from yeast deficient in orthologues of glycogen synthase kinase-3β or CDK5
  292. CDK5 : a new player at synapses
  293. Molecular characterization of a neuronal‐specific protein that stimulates the activity of CDK5
  294. Expression of CDK5 , p35, and CDK5 ‐associated kinase activity in the developing rat lens
  295. Nucleocytoplasmic CDK5 is involved in neuronal cell cycle and death in post-mitotic neurons
  296. p35 is required for CDK5 activation in cellular senescence
  297. Chronic mild stress in mice promotes cognitive impairment and CDK5 -dependent tau hyperphosphorylation
  298. CDK5 –p39 is a labile complex with the similar substrate specificity to CDK5 –p35
  299. CDK5 levels oscillate during the neuronal cell cycle: Cdh1 ubiquitination triggers proteosome-dependent degradation during S-phase
  300. Modulation of the JNK and p38 pathways by CDK5 protein kinase in a transgenic mouse model of Alzheimer’s disease
  301. CDK5 /p35 phosphorylates lemur tyrosine kinase‐2 to regulate protein phosphatase‐1C phosphorylation and activity
  302. Precursor of CDK5 activator, the 23 kDa subunit of tau protein kinase II: its sequence and developmental change in brain
  303. Synthesis and structure-activity relationship of 4-(1, 3-benzothiazol-2-yl)-thiophene-2-sulfonamides as cyclin-dependent kinase 5 (CDK5 )/p25 inhibitors
  304. CDK5 and Trio modulate endocrine cell exocytosis
  305. Structure–activity relationships of 3, 4-dihydro-1H-quinazolin-2-one derivatives as potential CDK5 inhibitors
  306. Microtubule-stimulated phosphorylation of tau at Ser202 and Thr205 by CDK5 decreases its microtubule nucleation activity
  307. CDK5 phosphorylates PLD2 to mediate EGF-dependent insulin secretion
  308. PKCδ regulates cortical radial migration by stabilizing the CDK5 activator p35
  309. Different mechanisms of CDK5 and CDK2 activation as revealed by CDK5 /p25 and CDK2/cyclin A dynamics
  310. Striatal dysregulation of CDK5 alters locomotor responses to cocaine, motor learning, and dendritic morphology
  311. CDK5 phosphorylates non-genotoxically overexpressed p53 following inhibition of PP2A to induce cell cycle arrest/apoptosis and inhibits tumor progression
  312. CDK5 -dependent regulation of Rho activity, cytoskeletal contraction, and epithelial cell migration via suppression of Src and p190RhoGAP
  313. Late recruitment of synapsin to nascent synapses is regulated by CDK5
  314. Neurodegeneration and neuroinflammation in CDK5 /p25-inducible mice: a model for hippocampal sclerosis and neocortical degeneration
  315. Peptides derived from CDK5 activator p35, specifically inhibit deregulated activity of CDK5
  316. Chromosomal mapping of human CDK2, CDK4, and CDK5 cell cycle kinase genes
  317. CDK5 -dependent phosphorylation of the Rho family GTPase TC10α regulates insulin-stimulated GLUT4 translocation
  318. CDK5 and the mystery of synaptic vesicle endocytosis
  319. Dpysl2 (CRMP2) and Dpysl3 (CRMP4) phosphorylation by CDK5 and DYRK2 is required for proper positioning of Rohon-Beard neurons and neural crest cells …
  320. High NaCl–induced activation of CDK5 increases phosphorylation of the osmoprotective transcription factor TonEBP/OREBP at threonine 135, which contributes to its …
  321. Local expression of mIgf-1 modulates ubiquitin, caspase and CDK5 expression in skeletal muscle of an ALS mouse model
  322. Neuron-specific CDK5 kinase is responsible for mitosis-independent phosphorylation of c-Src at Ser75 in human Y79 retinoblastoma cells
  323. Cooperative roles of c-Abl and CDK5 in regulation of p53 in response to oxidative stress
  324. Downregulation of neuronal CDK5 /p35 in opioid addicts and opiate-treated rats: relation to neurofilament phosphorylation
  325. CDK5 and the non-catalytic arrest of the neuronal cell cycle
  326. CDK5 targets active Src for ubiquitin-dependent degradation by phosphorylating Src (S75)
  327. CDK5 -mediated phosphorylation of δ-catenin regulates its localization and GluR2-mediated synaptic activity
  328. Potential neuroprotective flavonoid-based inhibitors of CDK5 /p25 from Rhus parviflora
  329. Microtubule association of the neuronal p35 activator of CDK5
  330. Phosphorylation of human high molecular weight neurofilament protein (hNF-H) by neuronal cyclin-dependent kinase 5 (CDK5 )
  331. CDK5 regulates cell-matrix and cell-cell adhesion in lens epithelial cells
  332. Involvement of cAMP in nerve growth factor-triggered p35/CDK5 activation and differentiation in PC12 cells
  333. Identification of ribosomal protein L34 as a novel CDK5 inhibitor
  334. Identification of a common protein association region in the neuronal CDK5 activator
  335. GTP-dependent secretion from neutrophils is regulated by CDK5
  336. Neuronal Cdc2-like protein kinase (CDK5 /p25) is associated with protein phosphatase 1 and phosphorylates inhibitor-2
  337. The cyclin-dependent kinases cdk2 and CDK5 act by a random, anticooperative kinetic mechanism
  338. Calpain inhibitor inhibits p35-p25-CDK5 activation, decreases tau hyperphosphorylation, and improves neurological function after spinal cord hemisection in rats
  339. Molecular roles of CDK5 in pain signaling
  340. Bortezomib action in multiple myeloma: microRNA-mediated synergy (and miR-27a/CDK5 driven sensitivity)?
  341. CDK5 and munc-18/p67 co-localization in early stage neurofibrillary tangles-bearing neurons in Alzheimer type dementia brains
  342. Intracellular localization of cyclin-dependent kinase 5 (CDK5 ) in mouse neuron: CDK5 is located in both nucleus and cytoplasm
  343. Both N-methyl-D-aspartate (NMDA) and non-NMDA receptors mediate glutamate-induced cleavage of the cyclin-dependent kinase 5 (CDK5 ) activator p35 in cultured …
  344. Co-purification and localization of Munc18-1 (p67) and CDK5 with neuronal cytoskeletal proteins
  345. The presence of active CDK5 associated with p35 in astrocytes and its important role in process elongation of scratched astrocyte
  346. CDK5 mediates vimentin ser56 phosphorylation during GTP‐induced secretion by neutrophils
  347. Protein-protein interactions in CDK5 regulation and function
  348. TGF-β1 sensitizes TRPV1 through CDK5 signaling in odontoblast-like cells
  349. EGFR/MEK/ERK/CDK5 -dependent integrin-independent FAK phosphorylated on serine 732 contributes to microtubule depolymerization and mitosis in tumor …
  350. CDK5 regulates activation and localization of Src during corneal epithelial wound closure
  351. Neuroprotective effect of TNFα against the β-amyloid neurotoxicity mediated by CDK5 kinase
  352. The structural perspective on CDK5
  353. Evidence of calpain/CDK5 pathway inhibition by lithium in 3-nitropropionic acid toxicity in vivo and in vitro
  354. CDK5 /p35 phosphorylates mSds3 and regulates mSds3-mediated repression of transcription
  355. CDK5 /p35 and Rho-kinase mediate ephrin-A5-induced signaling in retinal ganglion cells
  356. Dopamine D1 receptor activation induces tau phosphorylation via CDK5 and GSK3 signaling pathways
  357. Soluble alpha-APP (sAPPalpha) regulates CDK5 expression and activity in neurons
  358. Retinoic acid induces apoptosis of prostate cancer DU145 cells through CDK5 overactivation
  359. New approaches to the discovery of CDK5 inhibitors
  360. The CDK5 kinase downregulates ATP-gated ionotropic P2X3 receptor function via serine phosphorylation
  361. First BRET‐based screening assay performed in budding yeast leads to the discovery of CDK5 /p25 interaction inhibitors
  362. Forebrain-specific deletion of CDK5 in pyramidal neurons results in mania-like behavior and cognitive impairment
  363. Cyclin-dependent kinase 5 (CDK5 ) regulates the function of CLOCK protein by direct phosphorylation
  364. CDK5 mediates changes in morphology and promotes apoptosis of astrocytoma cells in response to heat shock
  365. At the fulcrum in health and disease: CDK5 and the balancing acts of neuronal structure and physiology
  366. Effects of natural flavones and flavonols on the kinase activity of CDK5
  367. Identification of novel substrates for CDK5 and new targets for CDK5 inhibitors using high‐density protein microarrays
  368. Silencing of CDK5 as potential therapy for Alzheimer’s disease
  369. Intrathecal administration of roscovitine inhibits CDK5 activity and attenuates formalin-induced nociceptive response in rats
  370. Purification of a 15-kDa cdk4-and CDK5 -binding protein.
  371. Cdk7 functions as a CDK5 activating kinase in brain
  372. CDK5 phosphorylation of FAK regulates centrosome-associated microtubules and neuronal migration
  373. Role of caspases, calpain and CDK5 in ammonia-induced cell death in developing brain cells
  374. Cyclin-dependent kinase 5 (CDK5 ): a potential therapeutic target for the treatment of neurodegenerative diseases and diabetes mellitus
  375. The notch signaling inhibitor dapt down‐regulates CDK5 activity and modulates the distribution of neuronal cytoskeletal proteins
  376. The involvement of CDK5 activator p35 in social isolation-triggered onset of early Alzheimer’s disease-related cognitive deficit in the transgenic mice
  377. Potentiation of tau aggregation by CDK5 and GSK3β
  378. Calpastatin, an endogenous calpain‐inhibitor protein, regulates the cleavage of the CDK5 activator p35 to p25
  379. Okadaic acid-stimulated degradation of p35, an activator of CDK5 , by proteasome in cultured neurons
  380. CDK5 is essential for soluble amyloid β-induced degradation of GKAP and remodeling of the synaptic actin cytoskeleton
  381. CDK5 in neuroskeletal dynamics
  382. Novel members of the cdc2-related kinase family in Drosophila: cdk4/6, CDK5 , PFTAIRE, and PITSLRE kinase.
  383. Synaptic deficits are rescued in the p25/CDK5 model of neurodegeneration by the reduction of β-secretase (BACE1)
  384. Regulation of kalirin by CDK5
  385. Single-nucleotide polymorphisms in the promoter of the CDK5 gene and lung cancer risk in a Korean population
  386. Up‐regulation of CDK5 /p35 by oxidative stress in human neuroblastoma IMR‐32 cells
  387. Calmodulin binding and CDK5 phosphorylation of p35 regulate its effect on microtubules
  388. The levels of CDK5 and p35 proteins and tau phosphorylation are reduced during neuronal apoptosis
  389. β2-Syntrophin is a CDK5 substrate that restrains the motility of insulin secretory granules
  390. Changes in the expression of novel CDK5 activator messenger RNA (p39nck5ai mRNA) during rat brain development
  391. X-ray irradiation promotes apoptosis of hippocampal neurons through up-regulation of CDK5 and p25
  392. CDK5 : mediator of neuronal development, death and the response to DNA damage
  393. Targeting p35/CDK5 signalling via CIP-peptide promotes angiogenesis in hypoxia
  394. Activation of latent cyclin‐dependent kinase 5 (CDK5 )–p35 complexes by membrane dissociation
  395. Design and synthesis of quinolin-2 (1H)-one derivatives as potent CDK5 inhibitors
  396. Cerebral ischemia, cell cycle elements and CDK5
  397. Characterization of a novel human CDK5 splicing variant that inhibits Wnt/β-catenin signaling
  398. Cell Cycle Regulatory Protein 5 (CDK5 ) is a Novel Downstream Target of ERK in Carboplatin Induced Death of Breast Cancer Cells (Supplementary Data)
  399. Structure–activity relationship study of 2, 4-diaminothiazoles as CDK5 /p25 kinase inhibitors
  400. Novel purine-based fluoroaryl-1, 2, 3-triazoles as neuroprotecting agents: synthesis, neuronal cell culture investigations, and CDK5 docking studies
  401. Neurabin-I is phosphorylated by CDK5 : implications for neuronal morphogenesis and cortical migration
  402. Resveratrol inhibits CDK5 activity through regulation of p35 expression
  403. p35, the non-cyclin activator of CDK5 , protects podocytes against apoptosis in vitro and in vivo
  404. Cyclin-dependent kinase 5 (CDK5 ) associated with Lewy bodies in diffuse Lewy body disease
  405. Reelin signaling and CDK5 in the control of neuronal positioning
  406. Increase of CDK5 is related to neurofibrillary pathology in progressive supranuclear palsy
  407. Apoptosis-associated tyrosine kinase is a CDK5 activator p35 binding protein
  408. Major CDK5 ‐dependent phosphorylation sites of amphiphysin 1 are implicated in the regulation of the membrane binding and endocytosis
  409. Outer Dense Fibers Serve as a Functional Target for CDK5 · p35 in the Developing Sperm Tail
  410. Estrogen-dependent facilitation on spinal reflex potentiation involves the CDK5 /ERK1/2/NR2B cascade in anesthetized rats
  411. Mutational and expression analysis of the reelin pathway components CDK5 and doublecortin in gangliogliomas
  412. Porcine brain neurofilament‐H tail domain kinase: Its identification as CDK5 /p26 complex and comparison with cdc2/cyclin B kinase
  413. Deregulation of CDK5 in Hippocampal sclerosis
  414. Increased expression of CDK5 /p25 in N2a cells leads to hyperphosphorylation and impaired axonal transport of neurofilament proteins
  415. Cortical development: CDK5 gets into sticky situations
  416. Changes in the activity of cdk2 and CDK5 accompany differentiation of rat primary oligodendrocytes
  417. Design, synthesis, and testing of an 6-O-linked series of benzimidazole based inhibitors of CDK5 /p25
  418. Cyclin-dependent kinase-5 (CDK5 ) and amyotrophic lateral sclerosis
  419. CDK5 regulatory subunit-associated protein 1-like 1 (CDKAL1) is a tail-anchored protein in the endoplasmic reticulum (ER) of insulinoma cells
  420. Drosophila lacking the CDK5 activator, p35, display defective axon guidance, age-dependent behavioral deficits and reduced lifespan
  421. An in silico approach for the discovery of CDK5 /p25 interaction inhibitors
  422. Ubiquitination of human AP-endonuclease 1 (APE1) enhanced by T233E substitution and by CDK5
  423. Combined inhibition of CDK5 and ROCK additively increase cell survival, but not the regenerative response in regenerating retinal ganglion cells
  424. Role of CDK5 in neuroprotection from serum deprivation by μ-opioid receptor agonist
  425. Role of p35/CDK5 in preplate splitting in the developing cerebral cortex
  426. CDK5 inhibitory peptide (CIP) inhibits CDK5 /p25 activity induced by high glucose in pancreatic beta cells and recovers insulin secretion from p25 damage
  427. Age-dependent pharmacokinetics and effect of roscovitine on CDK5 and Erk1/2 in the rat brain
  428. Induction of CDK5 activity in rat skeletal muscle after nerve injury
  429. Clausine Z, a new carbazole alkaloid from Clausena excavata with inhibitory activity on CDK5 .
  430. CDK5 : a novel role in learning and memory
  431. Crosstalk between CDK5 and MEK–ERK signalling upon opioid receptor stimulation leads to upregulation of activator p25 and MEK1 inhibition in rat brain
  432. Phosphorylation of AATYK1 by CDK5 suppresses its tyrosine phosphorylation
  433. CDK5 is a novel regulatory protein in PPARγ ligand-induced antiproliferation
  434. A sequel to the tale of p25/CDK5 in neurodegeneration
  435. CDK5 modulates β‐and δ‐catenin/Pin1 interactions in neuronal cells
  436. CDK5 phosphorylates dopamine D2 receptor and attenuates downstream signaling
  437. Neuroadaptations of CDK5 in cholinergic interneurons of the nucleus accumbens and prefrontal cortex of inbred alcohol‐preferring rats following voluntary alcohol …
  438. Kinetic studies of CDK5 /p25 kinase: phosphorylation of tau and complex inhibition by two prototype inhibitors
  439. Neuroadaptations of total levels of adenylate cyclase, protein kinase A, tyrosine hydroxylase, CDK5 and neurofilaments in the nucleus accumbens and ventral …
  440. Studying synergism of methyl linked cyclohexyl thiophenes with triazole: Synthesis and their CDK5 /p25 inhibition activity
  441. Cortical interneurons require p35/CDK5 for their migration and laminar organization
  442. Transient Enhanced Expression of CDK5 Activator p25 after Acute and Chronic d‐Amphetamine Administration
  443. CDK5 regulates cell–cell and cell–matrix adhesion in human keratinocytes
  444. Neuronal Cdc2-like kinases: neuron-specific forms of CDK5
  445. Inhibition of calpain-regulated p35/CDK5 plays a central role in sildenafil-induced protection against chemical hypoxia produced by malonate
  446. CDK5 interacts with Hif-1α in neurons: A new hypoxic signalling mechanism?
  447. p39, the primary activator for cyclin-dependent kinase 5 (CDK5 ) in oligodendroglia, is essential for oligodendroglia differentiation and myelin repair
  448. Involvement of septal CDK5 in the emergence of excessive anxiety induced by stress
  449. ODF1 phosphorylation by CDK5 /p35 enhances ODF1-OIP1 interaction
  450. α‐Chimaerin exists in a functional complex with the CDK5 kinase in brain
  451. CDK5 /p35 expression in the mouse ovary
  452. Absence of the CDK5 activator p35 causes adult-onset neurodegeneration in the central brain of Drosophila
  453. Inhibition of the CDK5 /MEF2 pathway is involved in the antiapoptotic properties of calpain inhibitors in cerebellar neurons
  454. 3-Nitropropionic acid activates calpain/CDK5 pathway in rat striatum
  455. DNA binding protein dbpA binds CDK5 and inhibits its activity
  456. Obesity-linked phosphorylation of PPARγ by CDK5 is a direct target of the anti-diabetic PPARγ ligands
  457. Dopamine signaling negatively regulates striatal phosphorylation of CDK5 at tyrosine 15 in mice
  458. The primary microcephaly 3 (MCPH3) interacting protein, p35 and its catalytic subunit, CDK5 , are centrosomal proteins
  459. A catch-and-release strategy for the combinatorial synthesis of 4-acylamino-1, 3-thiazoles as potential CDK5 inhibitors
  460. The kinase activity of EphA4 mediates homeostatic scaling-down of synaptic strength via activation of CDK5
  461. Phosphoproteome and transcriptome analysis of the neuronal response to a CDK5 inhibitor
  462. The molecular mystery of neuronal migration: FAK and CDK5
  463. AATYK1A phosphorylation by CDK5 regulates the recycling endosome pathway
  464. CDK5 in the adult non-demented brain
  465. p53, Apaf-1, caspase-3, and-9 are dispensable for CDK5 activation during cell death
  466. A CDK5 inhibitor enhances induction of insulin secretion by exendin-4 both in vitro and in vivo
  467. Association of neurofilament proteins with neuronal CDK5 activator
  468. Protein kinase CK2 is an inhibitor of the neuronal CDK5 kinase
  469. Distinct cellular compartment of cyclin-dependent kinase 5 (CDK5 ) and neuron-specific CDK5 activator protein (p35nck5a) in the developing rat cerebellum
  470. Influence of phosphorylation of p35, an activator of cyclin-dependent kinase 5 (CDK5 ), on the proteolysis of p35
  471. CDK5 regulates Rap1 activity
  472. Abnormal expression of CDK5 in focal cortical dysplasia in humans
  473. Expression of CDK5 and its activators in NT2 cells during neuronal differentiation
  474. The neuronal p35 activator of CDK5 is a novel F-actin binding and bundling protein
  475. Investigating the neuroprotective mechanism of action of a CDK5 inhibitor by phosphoproteome analysis
  476. Glutamate treatment and p25 transfection increase CDK5 mediated tau phosphorylation in SH-SY5Y cells
  477. The Xenopus laevis homologue to the neuronal cyclin-dependent kinase (CDK5 ) is expressed in embryos by gastrulation
  478. Evolution of isocortical organization. A tentative scenario including roles of reelin, p35/CDK5 and the subplate zone
  479. Hypomyelination phenotype caused by impaired differentiation of oligodendrocytes in Emx1-cre mediated CDK5 conditional knockout mice
  480. The cyclin‐dependent kinase inhibitor roscovitine inhibits kinase activity, cell proliferation, multicellular development, and CDK5 nuclear translocation in Dictyostelium …
  481. Early postnatal in vivo gliogenesis from nestin-lineage progenitors requires CDK5
  482. The role of the p35/CDK5 kinase in cortical development
  483. CDK5 phosphorylates a component of the HDAC complex and regulates histone acetylation during neuronal cell death
  484. The complex p25/CDK5 kinase in neurofibrillary degeneration and neuronal death: the missing link to cell cycle
  485. Peroxiredoxin-2 links CDK5 to neurodegeneration
  486. Hyperphosphorylation of tau and neurofilaments and activation of CDK5 and ERK1/2 in PTEN-deficient cerebella
  487. Developmental Alteration of the Expression and Kinase Activity of Cyclin‐Dependent Kinase 5 (CDK5 )/p35nck5a in the Rat Retina
  488. Structural basis for the different stability and activity between the CDK5 complexes with p35 and p39 activators
  489. Cyclin dependent kinase 5 (CDK5 )
  490. CDK5 activator p35 downregulates E-cadherin precursor independently of CDK5
  491. Regulation of membrane association and kinase activity of CDK5 –p35 by phosphorylation of p35
  492. PKC {zeta} Regulates CDK5 /P25 signaling during myogenesis
  493. CDK5 inhibits anterograde axonal transport of neurofilaments but not that of tau by inhibition of mitogen-activated protein kinase activity
  494. Role of CDK5 and Tau phosphorylation in heterotrimeric G protein–mediated retinal growth cone collapse
  495. Activity and regulation of p35/CDK5 kinase complex
  496. Interplay between the p53 tumor suppressor protein family and CDK5
  497. ik3-2, a relative to ik3-1/cables, is associated with cdk3, CDK5 , and c-abl
  498. Aberrant activation of CDK5 is involved in the pathogenesis of OPIDN
  499. CDK5 selectively affects the migration of different populations of neurons in the developing spinal cord
  500. Repeated acetyl‐l‐carnitine administration increases phospho‐Thr34 DARPP‐32 levels and antagonizes cocaine‐induced increase in CDK5 and phospho‐Thr75 …
  501. Novel interaction between nuclear co-activator CBP and the CDK5 activator binding protein-C53
  502. Cloning and characterization of the Drosophila melanogaster CDK5 homolog
  503. Alterations in cyclin-dependent protein kinase 5 (CDK5 ) protein levels, activity and immunocytochemistry in canine motor neuron disease
  504. Ginsenoside Rb1 attenuates beta-amyloid peptide (25-35)-induced hyperphosphorylation of tau protein through CDK5 signal pathway
  505. ERM proteins and CDK5 in cellular senescence
  506. Association between plasma biomarkers, CDK5 polymorphism and the risk of Alzheimer’s disease
  507. Immunohistochemical localization of CDK5 activator p39 in the rat brain
  508. CDK5 kinase regulates the association between adaptor protein Bem1 and GEF Cdc24 in the fungus Ustilago maydis
  509. Cyclin dependent kinase 5 (CDK5 ) mediated inhibition of the MAP kinase pathway results in CREB down regulation and apoptosis in PC12 cells
  510. Zebrafish Rohon-Beard neuron development: CDK5 in the midst
  511. Fuzhisan, a Chinese Herbal Medicine, Inhibits Beta-Amyloid-Induced Neurotoxicity and Tau Phosphorylation Through Calpain/CDK5 Pathway in Cultured Cortical …
  512. Identification and structure characterization of a Cdk inhibitory peptide derived from neuronal-specific CDK5 activator
  513. Distinct functions of CDK5 (Y15) phosphorylation and CDK5 activity in stress fiber formation and organization
  514. A scintillation proximity assay for studying inhibitors of human tau protein kinase II/CDK5 using a 96-well format
  515. CDK5 phosphorylates eNOS at Ser‐113 and regulates NO production
  516. CDK5 : Links to DNA damage
  517. Potent anti-diabetic actions of a novel non-agonist PPARγ ligand that blocks CDK5 -mediated phosphorylation
  518. The CDK5 homologue, Crp, regulates endocytosis and secretion in Dictyostelium and is necessary for optimum growth and differentiation
  519. Design and synthesis of 6-oxo-1, 6-dihydropyridines as CDK5 inhibitors
  520. CDK5 : an emerging kinase in pain signaling
  521. Increased accumbens CDK5 expression in rats after short-access to self-administered cocaine, but not after long-access sessions
  522. The CDK5 inhibitor olomoucine promotes corneal debridement wound closure in vivo
  523. Role of the pyrrolidine ring of proline in determining the substrate specificity of cdc2 kinase or CDK5
  524. p25/CDK5 is partially involved in neuronal injury induced by radiofrequency electromagnetic field exposure
  525. Involvement of cyclin d1‐CDK5 overexpression and mcm3 cleavage in bax‐associated spontaneous apoptosis and differentiation in an a253 human head and neck …
  526. Drosophila CDK5 is needed for locomotive behavior and NMJ elaboration, but seems dispensable for synaptic transmission
  527. Kinetic mechanistic studies of CDK5 /p25-catalyzed H1P phosphorylation: metal effect and solvent kinetic isotope effect
  528. The CDK5 /p35 kinases modulate leptin-induced STAT3 signaling
  529. Neuronal Differentiation and Patterning inXenopus: The Role of CDK5 and a Novel Activator Xp35. 2
  530. CDK5 is a dynamo at the synapse
  531. CDK5 : A regulator of epithelial cell adhesion and migration
  532. The CDK5 activator, p39, binds specifically to myosin essential light chain
  533. Prenatal cocaine and morphine alter brain cyclin-dependent kinase 5 (CDK5 ) activity in rat pups
  534. CDK5 : the” pathfinder” for new born neurons in adult hippocampus?
  535. Cloning and characterization of human IC53-2, a novel CDK5 activator binding protein
  536. Identifying novel substrates for mouse CDK5 kinase using the yeast Saccharomyces cerevisiae
  537. CDK5 , CRMP2 and NR2B in spinal dorsal horn and dorsal root ganglion have different role in pain signaling between neuropathic pain model and inflammatory pain …
  538. CDK5 variant 1 (CDK5 -v1), but not full-length CDK5 , is a centrosomal protein
  539. Synthesis and evaluation of new potent inhibitors of CK1 and CDK5 , two kinases involved in Alzheimer’s disease
  540. Synergistic gene expressions of cyclin E, cdk2, CDK5 and E2F-1 during the prolactin-induced G1/S transition in rat Nb2 pre-T lymphoma cells.
  541. CDK5 in the centriolar appendages mediates cenexin1 localization and primary cilia formation
  542. CDK5 -induced neuronal cell death: The activation of the conventional Rb-E2F G1 pathway in post-mitotic neurons
  543. Localization of CDK5 in the midbody and increased aneuploidy in CDK5 -/- cells
  544. Comparison of munc-18 and CDK5 expression in the nervous system during mouse embryogenesis
  545. Role of a CDK5 -associated protein, p35, in herpes simplex virus type 1 replication in vivo
  546. CDK5 : A new lead to survival
  547. CDK5 interacts with Slo and affects its surface expression and kinetics through direct phosphorylation
  548. When good CDK5 turns bad
  549. Increased immunoreactivity of CDK5 activators in hippocampal sclerosis
  550. Identification of non-muscle myosin heavy chain as a substrate for CDK5 and tool for drug screening
  551. Development of an assay to screen for inhibitors of tau phosphorylation by CDK5
  552. CDK5 expression and association with p35nck5a in early stages of rat cerebellum neurogenesis; tyrosine dephosphorylation and activation in post-mitotic neurons
  553. A cdc2-like kinase distinct from CDK5 is associated with neurofilaments
  554. Novel aspects in structure–activity relationships of profiled 1-aza-9-oxafluorenes as inhibitors of Alzheimer’s disease-relevant kinases cdk1, CDK5 and gsk3β
  555. Novel insights into the beneficial and detrimental actions of CDK5
  556. Direct and indirect roles of CDK5 as an upstream regulator in the JNK cascade: relevance to neurotoxic insults in Alzheimer’s disease
  557. Structural insights into CDK5 activation by a neuronal CDK5 activator
  558. The neuronal cyclin-dependent kinase 5 activator p35Nck5a and CDK5 activity in monocytic cells
  559. Mechanism of CDK5 activation revealed by steered molecular dynamics simulations and energy calculations
  560. Decreasing levels of the CDK5 activators, p25 and p35, reduces excitotoxicity in striatal neurons
  561. Ras target protein canoe is a substrate for Cdc2 and CDK5 kinases
  562. Identification of p10 as a neurotoxic product generated from the proteolytic cleavage of the neuronal CDK5 activator
  563. A novel mechanism of non-Aβ component of Alzheimer’s disease amyloid (NAC) neurotoxicity. Interplay between p53 protein and cyclin-dependent kinase 5 (CDK5 )
  564. Overexpression of CDK5 or non-phosphorylatable retinoblastoma protein protects septal neurons from oxygen–glucose deprivation
  565. CDK5 at the junction
  566. The CDK5 inhibitor roscovitine strongly inhibits glucose uptake in 3T3‐L1 adipocytes without altering GLUT4 translocation from internal pools to the cell surface
  567. Molecular cloning and characterisation of a mouse gene encoding an isoform of the neuronal cyclin-dependent kinase 5 (CDK5 ) activator
  568. Rho/ROCK and CDK5 effects on phosphorylation of a β-thymosin repeat protein in Hermissenda
  569. A dinoflagellate CDK5 ‐like cyclin‐dependent kinase
  570. Differential regulation of CDK5 and c-Fos expression by morphine in the brain of Lewis and Fischer 344 rat strains
  571. Production of Mouse ES Cells Homozygous for CDK5 -Phosphorylated Site Mutation in c-src Alleles
  572. Binding mechanism of inhibitors to CDK5 /p25 complex: free energy calculation and ranking aggregation analysis
  573. Ontogeny of abnormal brain development in CDK5 (-/-) mice
  574. Differential regulation of the CDK5 ‐dependent phosphorylation sites of inhibitor‐1 and DARPP‐32 by depolarization
  575. Effect of CDK5 antagonist on L-dopa-induced dyskinesias in a rat model of Parkinson’s disease
  576. Cyclin-Dependent Kinase 5 (CDK5 ) modulates signal transduction pathways regulating neuronal survival
  577. Changes of CDK5 , p35 and p53 gene expression levels in arsenic-induced neural cell apoptosis
  578. Involvement of CDK5 in synaptic plasticity, and learning and memory
  579. Therapeutic potential of CDK5 inhibitors to promote corneal epithelial wound healing
  580. No association of polymorphisms in the CDK5 , NDEL1, and LIS1 with autism in Chinese Han population
  581. No association of CDK5 genetic variants with Alzheimer’s disease risk
  582. Hippocampal mossy fiber sprouting and CDK5 /p35 expressions in the pentylenetetrazole kindling rat model
  583. Regulation and function of CDK5 in the nucleus
  584. The kinase activity of CDK5 and its regulation
  585. Molecular dynamic simulations give insight into the mechanism of binding between 2-aminothiazole inhibitors and CDK5
  586. CDK5 , a journey from brain to pain: lessons from gene targeting
  587. Expression of CyclinE and CDK5 in lung cancer
  588. CDK5 checks p27kip1 in neuronal migration
  589. CDK5 inhibition diminishes pancreatic cancer tumorigenesis and metastasis
  590. Cloning and Spatio-Temporal Expression of Porcine CDK5 and CDK5 R1(p35) Genes
  591. Cell cycle-related genes p57kip2, CDK5 and Spin in the pathogenesis of neural tube defects
  592. Involvement of CDK5 /p35 and tau protein in the hippocampal mossy fiber sprouting in the PTZ kindling model
  593. Addressing the complex etiology of Alzheimer’s disease: the role of p25/CDK5
  594. 1001 CDK5 is Involved in Oxaliplatin Response and Resistance Acquisition Through Regulation of STAT3 Transcription Factor
  595. Expression and activity of CDK5 /p35 in a rat model of trigeminal neuropathic pain
  596. p35 and p25 expressions and CDK5 kinase activity in primary cultured rat hippocampal neurons with X-ray exposure
  597. Association of rs2069459 in the CDK5 gene with dyslexia in a German cohort
  598. Tyrosine hydroxylase expression and CDK5 kinase activity in ataxic cerebellum
  599. CRMP Family Protein: Novel Targets for CDK5 That Regulates Axon Guidance, Synapse Maturation, and Cell Migration
  600. Pro-apoptotic signaling pathway by CDK5 and MEKK1
  601. Protein Kinase Cζ Regulates CDK5 /p25 Signaling during Myogenesis
  602. Developmental mRNA Expression of CDK5 and its Putative Regulators, p67 and p35, in Rat Brain
  603. CDK5 is present in sea urchin and starfish eggs and embryos and can interact with p35, cyclin E and cyclin B3
  604. The role of CDK5 in non‐neuronal tissues
  605. A Novel Role for Lymphocyte Expression of the Cyclin-Dependent Kinase 5 (CDK5 ) in the Generation of Allogeneic T Cell Responses After BMT
  606. Cyclin dependent kinase 5 (CDK5 ): a possible link between neuropathologies and diabetes
  607. Regulation of the NAD+-dependent deacetylase SIRT2 by CDK5
  608. Loss of CDK5 sensitizes ovarian cancer cells to paclitaxel by enhancing intracellular retention
  609. Neuronal Motility and Structure: CDK5 Pathways
  610. CDK5 /p35 activity is essential for eye growth and retinal lamination in zebrafish
  611. Role of CDK5 activators in psychiatric diseases, learning and memory
  612. Cyclin-Dependent Kinase 5 (CDK5 ): Linking Synaptic Plasticity and Neurodegeneration
  613. Cyclin-Dependent Kinase 5 (CDK5 ): Preparation and Measurement of Kinase Activity
  614. For new neurons in an old brain, CDK5 shows the way
  615. Alzheimer’s disease: No effect of the CDK5 gene on CSF biomarkers, neuropathology or disease risk
  616. Identification of a human cDNA encoding a kinase-defective CDK5 isoform
  617. CDK5 keeps memory on Trk
  618. CDK5 in presynapses
  619. CDK5 as a drug target for Alzheimer’s disease
  620. Identification of Pctaire1 as a p35-interacting protein and a novel substrate for CDK5
  621. An Unusual Member of the Cdk Family: CDK5 .
  622. CDK5 and Mekk1 mediate a Pro-Apoptotic Signaling Response to Endoplasmic Reticulum Stress in a Drosophila Model of Autosomal Dominant Retinitis …
  623. Design and Synthesis of Benzimidazoles as CDK5 Inhibitors and Progress Toward the Total Synthesis of Tubulysin D
  624. Modulation of transient receptor potential cation channel, subfamily A, member 1 (TRPA1) activity by CDK5
  625. The study of the role of cyclin-dependent kinase 5 (CDK5 ) during cell death
  626. CDK5 activity is required for BDNF-stimulated neuronal survival and synaptic plasticity
  627. S-nitrosylation of CDK5 regulates its kinase activity and dendrite growth during neuronal development
  628. Identification of TrkB as a p35 interacting protein and a CDK5 substrate
  629. Unraveling CDK5 -mediated signaling in Alzheimer’s disease pathogenesis
  630. Src Binds Directly to CDK5 Without Requirement for CDK5 Activity or Phosphorylation
  631. ANKRA2 interacts with p35 and is a substrate for CDK5 /p35
  632. Understanding the role of CDK5 in activity-induced gene expression during dendrite development
  633. CDK5 Regulates Corneal Epithelial Cell Adhesion and Migration in vitro
  634. A peptide derived from cyclinâ dependent kinase activator (p35) specifically inhibits CDK5 activity and phosphorylation of tau protein in transfected cells
  635. CDK5 Activity Regulates Myosin Phosphorylation in Lens Epithelial Cells
  636. CDK5 Is Essential for Recruitment of Active Src to Focal Adhesions
  637. Phosphorylating Activity of the Alzheimer’s Disease-associated Kinase CDK5 is Selectively Inhibited ill vitro
  638. Involvement of CDK5 /p35 in EphB2-dependent dendritic spine development
  639. CDK5 is a membrane-associated protein kinase whose mislocalization induces neuronal cell death
  640. CDK5 : A Contributor to the Insulin Phenotype of Transdifferentiated β Cells
  641. Are chemical inhibitors an effective way to study the role of Cyclin Dependent Kinase 5 (CDK5 ) in neuronal and pancreatic development? Comparative kinase assays …
  642. CDK5 Specifically Affects Rho Activation Required for Myosin-Dependent Contraction and Stress Fiber Maintenance in Spreading Lens Epithelial Cells
  643. Functional characterization of CDK5 -mediated phosphorylation of endophilin B1 in macroautophagy in models of parkinson’s disease
  644. … PARP-1, PARP-2 and CDK5 proteins and chromatin implication; Facteurs modulant la radiosensibilite: Role des proteines PARP-1, PARP-2 et CDK5 et implication de …
  645. The role of CDK5 in endophilinB1-mediated regulation of NGF/TrkA trafficking
  646. Expression and distribution of cyclin-dependent kinase 5 (CDK5 ) in the developing rat brain
  647. Phosphorylation of TonEBP/OREBP by cyclin dependent kinase 5 (CDK5 ) mediates its NaCl‐induced nuclear translocation
  648. CDK5 , a cdk which is required for myogenesis, shows marked changes in sub-cellular distribution during early myogenesis and at the G1-S transition in fibroblasts.
  649. The role of cyclin-dependent kinase 5 (CDK5 ) in Neurodegeneration
  650. Expression and activity of CDK5 /p39 during rats Vc development
  651. Inhibition of CDK5 activity alters localization of cSRC and promotes corneal wound healing in vitro
  652. Functional investigation of the neuronal CDK5 activator p35 in the regulation of actin dynamics
  653. Mice overexpressing dominant negative CDK5 in the pancreatic beta-cells show the phenotype of type 1 diabetes mellitus
  654. The role of CDK5 in EphB-mediated synaptogenesis
  655. The CDK5 Activating Protein, p39, Interacts With Nonmuscle Myosin Light Chain
  656. CDK5 modulates the cell cycle, apoptosis and paclitaxel sensitivity in human ovarian cancer cells with wild-type p53 function
  657. CDK5 Phosphorylated at Tyrosine-15 Co-Localizes With Early Focal Adhesions in Cultured Human Corneal Limbal Epithelial Cells
  658. Dynamics of human CDK2 and CDK5 studied by computer simulations
  659. CDK5 expression of spinal motor neuron in immune-mediated injury
  660. CDK5 : new insights into its biological function in human brain microvascular endothelial cells
  661. Cell-Cell Junctions in a CDK5 -Deficient Corneal Epithelial Cell Line
  662. Inhibition of CDK5 Attenuates Experimental Autoimmune Uveitis
  663. Truncation of CDK5 activator p35 induces intensive phosphorylation of Ser202/Thr205 of human tau.
  664. Function and regulation of the neuronal CDK5 /p35 kinase in the control of protein translation
  665. Molecular characterization and structural determination of a CDK5 inhibitory peptide derived from neuronal CDK5 activator
  666. Using Chemical Inhibitors to Study the Role of the Cyclin Dependent Kinase 5 (CDK5 ) Protein in the Nerve Growth Factor Induced Neuronal Differentiation of PC12 …
  667. The differential expression of P57kip2 and CDK5 in retinoic acid-induced neural tube defects
  668. The expression and localization of CDK5 /p35 kinase in human malignant glioma cells.
  669. Alteration in Neuronal Architecture Resulting from the Chemical Inhibition of CDK5 during Neuronal Differentiation
  670. Identification and characterization of a common protein association region in the neuronal CDK5 activator
  671. Cyclin Dependent Kinase 5 (CDK5 ): the possible connection in insulin‐related neurodegenerative diseases
  672. Baculovirus co-expression and purification of CDK5 and p35nck5a
  673. Interaction Between the CDK5 Activating Proteins, p39 and p35, and an Alternatively Spliced Zinc-Finger Protein in Lens
  674. The CDK5 /p35 Pathway
  675. Role Of Calpains And CDK5 In XOR Activation In Pulmonary Microvascular Endothelial Cells Exposed To Hypoxia
  676. Radiosensitivity modulating factors: Role of PARP-1, PARP-2 and CDK5 proteins and chromatin implication
  677. The role of CDK5 /p35 and cPLA2/LOX in neuroinflammation and neurodegeneration
  678. CDK5 inhibition suppresses pancreatic cancer tumorigenesis and metastasis
  679. Identification and characterization of endophilin B1 as a p35 interacting protein and a CDK5 substrate
  680. Regulation of synaptic calcium influx by CDK5 phosphorylation
  681. 419 ALL-TRANS RETINOIC ACID INDUCED CELL CYCLE ARREST AND APOPTOSIS OF DU145 CELLS THROUGH CDK5 ACTIVATION
  682. Enhanced expression of CDK5 in neuronal differentiation from neurospheres by cell cycle blocker treatment
  683. Abstract A8: CDK5 modulates ErbB2/3 phosphorylation and prostate cancer cell growth
  684. The effect of endurance training on gene expression of CDK5 in sensory neurons of male wistar rats with diabetic neuropathy
  685. CDK5 -Dependent Regulation of Neuronal MEK1
  686. Effects of lithium on CDK5 and PP2A expressions in chronic aluminum exposure rats
  687. The CDK5 activator p39 specifically links muskelin to myosin and regulates stress fiber organization and contraction
  688. Potentiation of GSK-3-catalyzed Alzheimer-like Phosphorylation of Human Tau by CDK5
  689. Abstract B45: The short-term effects of arsenic on CDK5 -dependent apoptosis of prostate cancer cells
  690. The CDK5 Activating Protein, p39, Complexes With Muskelin to Regulate Cell Adhesion on Thrombospondin
  691. The role of flavinoids in the inhibition of CDK5 in neuronal differentiation
  692. The protein kinase CDK5 : Structural aspects, roles in neurogenesis and involvement in Alzheimer’s pathology
  693. Insulin disregulation and neurodegeneration: a possible role for CDK5
  694. Extensive mutational analysis of CDK5 and CDK5 R1 in patients with non-syndromic mental retardation reveals novel variants in CDK5 R1 3′-UTR
  695. PI3K-dependent motility of prostate cancer cells is mediated through post-transcriptional control of the p35 regulatory subunit of CDK5
  696. Effect of donepezil hydrochloride on the Calpain Ⅰ-CDK5 pathway expression in the hippocampus of mice with vascular dementia
  697. CDK5 -mediated phosphorylation and autophagy of Raf kinase inhibitor protein regulate neuronal death in Parkinson’s disease
  698. CDK5 -MEDIATED HYPERPHOSPHORYLATION CONTRIBUTES TO THE LOSS-OF-SIRT1 FUNCTION DURING THE DEVELOPMENT OF ENDOTHELIAL …
  699. CDK5 /p35 Regulates Neuronal Migration
  700. Cyclin-dependent Kinase 5 (CDK5 ) and p35 in Lewy Bodies (LB)
  701. CDK5 as a Therapeutic Target in Prostate Cancer Metastasis
  702. Characterization of p35, a neuronal activator of CDK5 , as a novel microtubule-associated protein
  703. The CDK5 Activating Protein P39 Directly Links Muskelin to Myosin and Stress Fibers
  704. Effect of heme oxygenase-1 on CDK5 -ATM-P53 signal transduction pathway in rat hippocampal neurons subjected to oxygen-glucose deprivation injury
  705. CDK5 May Be an Atypical Kinase, but Not in the Way You Think
  706. CDK5 and Neuregulin-1 Signaling
  707. Regulation of CDK5 unveiled by its structure with the p25 neuronal activator
  708. Retinoic Acid Causes CDK5 -Dependent Apoptosis of Cervical Cancer Cell Line
  709. Memory and Learning: CDK5 tells a tail to remember
  710. The CDK5 Inhibitor, Roscovitine, Protects Retinal Neurons From Chemical Anoxia, In Vitro, And Excitotoxicity, In Vivo
  711. Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPARg by CDK5
  712. Monte Carlo and dynamics simulations of CDK5 Kinase inhibitor peptides p5 in aqueous solution
  713. Intracellular Localization of Cyclin-dependent Kinase 5 (CDK5 ) in the Protozoan Tetrahymena Pyriformis
  714. CDK5 Kinase Activity, Caspase-3 Expression and Synaptic Structural Plasticity in Infra-limbic Cortex of Rats with Conditioned Fear
  715. The protective effects of TanIIA on neurotoxicity induced by β-amyloid protein through the CDK5 /P35 pathway in cultured primary neurons
  716. Phosphorylation of Drp1 by CDK5 (cyclin dependent kinase 5) involves in mitochondrial dynamics regulation
  717. Abstract A058: t-Darpp is phosphorylated by cdk1 and CDK5 in HER2+ breast cancer cells
  718. RNAi Screen of the Druggable Genome Identifies Modulators of Proteasome Inhibitor Sensitivity in Myeloma Including CDK5 .
  719. Phosphorylation of synthetic peptides containing proline homologs by cdc2 kinase or CDK5
  720. Role of cyclin dependent kinase 5 (CDK5 ) and c‐Abl in high NaCl‐induced nuclear localization of the osmoprotective transcription factor, TonEBP/OREBP
  721. CDK5 activator p35 downregulates E-cadherin precursor independently of CDK5
  722. Expression and activity of CDK5 /p39 during rats Vc development.
  723. Calpain inhibitor inhibits p35-p25-CDK5 activation, decreases tau hyperphosphorylation, and improves neurological function after spinal cord hemisection in rats
  724. Role of CDK5 on ATM phosphorylation in neuronal death induced by DNA damage
  725. A study of the function of CDK5 in oligodendrocytes differentiation by using conditional knockout strategy
  726. The Role of CDK5 in the Regulation of Dopamine Neurotransmission, Neuronal Excitability, and Reward-Related Behavior
  727. Subcellular Translocation of Extracellular Signal-regulated Kinases (ERKs) and Cyclin-dependent Kinase 5 (CDK5 ) in Alzheimer’s Disease and in a Cell Model of …
  728. CDK5 PHOSPHORYLATION OF MUNC18-1 ENHANCES SYNAPTIC TRANSMISSION
  729. CDK5 protects huntingtin
  730. CDK5 and Mitochondrial Cell Death Pathways
  731. Cell-Penetrating Fragments of the CDK5 Regulatory Subunit Are Protective in Models of Neurodegeneration
  732. Activity-Dependent Phosphorylation of p70 Ribosomal s6 Kinase (p70S6K) by CDK5 Is Required for Dendritic Spine Maturation
  733. Functional characterization of CDK5 -mediated phosphorylation of RapGEF2 in cortical development
  734. CDK5 -dependent Phosphorylation of Mst3 Regulates Radial Migration through Modulating RhoA Activity
  735. CDK5 in Dendrite and Synapse Development: Emerging Role as a Modulator of Receptor Tyrosine Kinase Signaling
  736. CDK5 -mediated PI3K/Akt pathway coupling with up-regulation of Bcl-2 confers differentiated neuroblastoma resistance to apoptosis
  737. The role of thep35/CDK5 kinase in cortical development
  738. The roles of CDK5 in neuronal development and neurodegeneration
  739. Increase of CDK5 and p35 during Retinoic Acid-Induced Neuronal Differentiation of SK-N-BE (2) C cells
  740. Regulation of cyclin-dependent kinase 5 (CDK5 ) in cell death
  741. Regulators of neurotrophin-mediated Trk signaling: SLAM-associated protein (SAP) and cyclin-dependent kinase 5 (CDK5 )
  742. Unravelling the complex role of CDK5 in the developing cerebral cortex
  743. Microtubule-dependent phosphorylation of Tau by CDK5 kinase modulates its activity on microtubule dynamics
  744. Molecular modeling and SAR studies of CDK5 /p25 selective inhibitors
  745. P1–416: APP processing and cell cycle reentry signaling pathways are involved in p25/CDK5 –mediated neurodegeneration
  746. Regulation of the p35/CDK5 kinase in neuronal development and neurodegenerative disease
  747. Molecular and cellular mechanisms of the cyclin-dependent kinase 5 (CDK5 ) in neocortical migration and layer formation
  748. CDK5 in neuronal development and potential regulation of kinesins
  749. Tolfenamic Acid Reduces Total, Phosphorylated Tau and CDK5 Levels via a Transcriptional Pathway: Implications for Dementia and Tauopathies
  750. Tau Phosphorylation by CDK5 and GSK-3beta: Insights into Physiological Phosphorylation and Pathological Phosphorylation in FTDP-17
  751. CDK5 Modulation of MAPK Signaling Regulates Neuronal Survival
  752. MOLECULAR MECHANISMS IN P25/CDK5 -MEDIATED NEUROINFLAMMATION AND SUBSEQUENT NEURODEGENERATION: THERAPEUTIC …
  753. In vitro modelling of tau phosphorylating kinases: emphasis of CDK5
  754. Mice lacking phosphatase PP2A subunit PR61/BTδ (Ppp2r5d) develop spatially restricted tauopathy by deregulation of CDK5 and GSK3β
  755. P3–277: Severe neurodegeneration is intimately related to inflammation in CDK5 /p25 inducible mice
  756. From CDK5 to Alzheimer’s disease: future challenges
  757. Expression studies of the proteolytic p10 fragment of the neuronal CDK5 activator in mammalian cells
  758. The functional roles of cyclin-dependent kinase 5 (CDK5 ) activators in neuronal and muscle cell differentiation
  759. p35 and p39 mediated regulation of CDK5 function
  760. Supplemental Data Article Deregulation of HDAC1 by p25/CDK5 in Neurotoxicity
  761. Levels of activators of cyclin-dependent protein kinase 5 (CDK5 ) p25 and p35 in Alzheimer’s disease
  762. Homology Modeling of apo-CDK5 and Insights into Structure-Based Inhibitor Design
  763. Hyperphosphorylation of tau and neurofilament by constitutive activation of CDK5 in PTEN deficient cerebellum
  764. Erratum to CDK5 and MAPK are associated with complexes of cytoskeletal proteins in rat brain [Mol. Brain Res. 76 (2000) 229–236]
  765. The CDK5 -p35 kinase associates with the Golgi apparatus and regulates membrane traffic
  766. The effects of Calpain-CDK5 -p35 pathway inhibition on rat spinal cord injury, acute pain, and morphine tolerance
  767. Proteins regulating cyclin dependent kinases Cdk4 and CDK5
  768. SNAP-25 and CDK5 as exocytotic regulators: Consequences for synaptic function and insulin release
  769. Identification and characterization of protein kinase CK2 as a novel interacting protein of neuronal CDK5 kinase and its functional role in microtubule dynamics
  770. The Regulation and Function of CDK5 in Cellular Senescence and Tumorigenesis
  771. more severe than those of Reeler (5), Mdab1 (19), CDK5 (20), P35 (21), and Pafah1b1 (22) mutants, which suggests that Lhx5 may control a different pathway …
  772. P25/CDK5 Inhibitors for Alzheimer’s Disease Therapeutics
  773. Protein Conformational Plasticity: the “off‐on” Switching Movement in CDK5
  774. Physiological and pathological phosphorylation of tau by CDK5
  775. CDK5 activity in the brain–multiple paths of regulation
  776. The role of CDK5 in Alzheimer’s disease
  777. CDK5 disruption attenuates tumor PD-L1 expression and promotes antitumor immunity
  778. An ERK/CDK5 axis controls the diabetogenic actions of PPARγ
  779. The emerging role of CDK5 in cancer
  780. LncRNA TTN-AS1 promotes migration, invasion, and epithelial mesenchymal transition of lung adenocarcinoma via sponging miR-142-5p to regulate CDK5
  781. Inhibition of p25/CDK5 attenuates tauopathy in mouse and iPSC models of frontotemporal dementia
  782. Astrocyte NMDA receptors’ activity sustains neuronal survival through a CDK5 –Nrf2 pathway
  783. Targeted epigenetic remodeling of the CDK5 gene in nucleus accumbens regulates cocaine-and stress-evoked behavior
  784. Biological functions of CDK5 and potential CDK5 targeted clinical treatments
  785. … MALAT1 inhibits neuron apoptosis and neuroinflammation while stimulates neurite outgrowth and its correlation with miR-125b mediates PTGS2, CDK5 and FOXQ1 in …
  786. Memory enhancement by targeting CDK5 regulation of NR2B
  787. Downregulation of miR-124 in MPTP-treated mouse model of Parkinson’s disease and MPP iodide-treated MN9D cells modulates the expression of the calpain/CDK5 …
  788. Targeting STAT3/miR-21 axis inhibits epithelial-mesenchymal transition via regulating CDK5 in head and neck squamous cell carcinoma
  789. Deactivation of excitatory neurons in the prelimbic cortex via CDK5 promotes pain sensation and anxiety
  790. Melatonin attenuates MPTP-induced neurotoxicity via preventing CDK5 -mediated autophagy and SNCA/α-synuclein aggregation
  791. Loss of mitofusin 2 links beta‐amyloid‐mediated mitochondrial fragmentation and CDK5 ‐induced oxidative stress in neuron cells
  792. A kinase of many talents: non-neuronal functions of CDK5 in development and disease
  793. CDK5 phosphorylates DRP1 and drives mitochondrial defects in NMDA-induced neuronal death
  794. CDK5 -dependent phosphorylation and nuclear translocation of TRIM59 promotes macroH2A1 ubiquitination and tumorigenicity
  795. CDK5 -dependent phosphorylation of CaV3. 2 T-type channels: possible role in nerve ligation-induced neuropathic allodynia and the compound action potential in …
  796. Tale of the good and the bad CDK5 : remodeling of the actin cytoskeleton in the brain
  797. Ischemic stroke injury is mediated by aberrant CDK5
  798. Folding of the cerebral cortex requires CDK5 in upper-layer neurons in gyrencephalic mammals
  799. Activation of CDK5 /p25 and tau phosphorylation following chronic brain hypoperfusion in rats involves micro RNA‐195 down‐regulation
  800. Loss of CDK5 in breast cancer cells promotes ROS-mediated cell death through dysregulation of the mitochondrial permeability transition pore
  801. CDK5 -dependent inhibitory phosphorylation of Drp1 during neuronal maturation
  802. Stress-induced CDK5 activation disrupts axonal transport via Lis1/Ndel1/Dynein
  803. Basolateral amygdala bidirectionally modulates stress-induced hippocampal learning and memory deficits through a p25/CDK5 -dependent pathway
  804. CDK5 functions as a tumor promoter in human colorectal cancer via modulating the ERK5–AP-1 axis
  805. CDK5 : key regulator of apoptosis and cell survival
  806. CDK5 induces constitutive activation of 5-HT6 receptors to promote neurite growth
  807. Metformin ameliorates synaptic defects in a mouse model of AD by inhibiting CDK5 activity
  808. Physiological and pathological roles of CDK5 : potential directions for therapeutic targeting in neurodegenerative disease
  809. The role of CDK5 in tumours and tumour microenvironments
  810. CDK5 at crossroads of protein oligomerization in neurodegenerative diseases: facts and hypotheses
  811. CDK5 activator protein p25 preferentially binds and activates GSK3β
  812. CDK5 knockdown prevents hippocampal degeneration and cognitive dysfunction produced by cerebral ischemia
  813. … synaptic GTPase-activating protein (synGAP) by Ca2+/calmodulin-dependent protein kinase II (CaMKII) and cyclin-dependent kinase 5 (CDK5 ) alters the ratio …
  814. mPTP opening caused by CDK5 loss is due to increased mitochondrial Ca2+ uptake
  815. A Tale of the Good and Bad: Remodeling of the Microtubule Network in the Brain by CDK5
  816. CDK5 –Foxo3 axis: initially neuroprotective, eventually neurodegenerative in Alzheimer’s disease models
  817. CDK5 /FBW7-dependent ubiquitination and degradation of EZH2 inhibits pancreatic cancer cell migration and invasion
  818. Autosomal recessive lissencephaly with cerebellar hypoplasia is associated with a loss-of-function mutation in CDK5
  819. CDK5 -mediated phosphorylation and stabilization of TPX2 promotes hepatocellular tumorigenesis
  820. Mechanisms of HIV-1 Tat neurotoxicity via CDK5 translocation and hyper-activation: role in HIV-associated neurocognitive disorders
  821. … peroxisome proliferator-activated receptor γ (PPARγ) ligand UHC1 blocks PPARγ phosphorylation by cyclin-dependent kinase 5 (CDK5 ) and improves insulin …
  822. Neuroprotective mechanisms mediated by CDK5 inhibition
  823. Physiological concentrations of amyloid beta regulate recycling of synaptic vesicles via alpha7 acetylcholine receptor and CDK5 /calcineurin signaling
  824. Development of CDK2 and CDK5 dual degrader TMX‐2172
  825. AC1MMYR2 impairs high dose paclitaxel-induced tumor metastasis by targeting miR-21/CDK5 axis
  826. Knockdown of CDK5 down-regulates PD-L1 via the ubiquitination-proteasome pathway and improves antitumor immunity in lung adenocarcinoma
  827. Endothelial CDK5 deficit leads to the development of spontaneous epilepsy through CXCL1/CXCR2-mediated reactive astrogliosis
  828. Inhibition of endothelial CDK5 reduces tumor growth by promoting non-productive angiogenesis
  829. CDK5 knocking out mediated by CRISPR-Cas9 genome editing for PD-L1 attenuation and enhanced antitumor immunity
  830. Perinatal exposure to lead (Pb) promotes Tau phosphorylation in the rat brain in a GSK-3β and CDK5 dependent manner: Relevance to neurological disorders
  831. CDK5 -mediated phosphorylation of RapGEF2 controls neuronal migration in the developing cerebral cortex
  832. Crosstalk between CDK5 /p35 and ERK1/2 signalling mediates spinal astrocyte activity via the PPARγ pathway in a rat model of chronic constriction injury
  833. The inhibition of CDK5 activity after hypoxia/ischemia injury reduces infarct size and promotes functional recovery in neonatal rats
  834. Dual inhibition of GSK3β and CDK5 protects the cytoskeleton of neurons from neuroinflammatory-mediated degeneration in vitro and in vivo
  835. Zinc induces CDK5 activation and neuronal death through CDK5 -Tyr15 phosphorylation in ischemic stroke
  836. TIGAR regulates DNA damage and repair through pentosephosphate pathway and CDK5 -ATM pathway
  837. Inhibition of CDK5 increases osteoblast differentiation and bone mass and improves fracture healing
  838. CDK5 : a unique CDK and its multiple roles in the nervous system
  839. CDK5 and its substrates, Dcx and p27kip1, regulate cytoplasmic dilation formation and nuclear elongation in migrating neurons
  840. Fusobacterium nucleatum Promotes the Progression of Colorectal Cancer Through CDK5 -Activated Wnt/β-Catenin Signaling
  841. Phosphorylation of cyclin-dependent kinase 5 (CDK5 ) at Tyr-15 is inhibited by CDK5 activators and does not contribute to the activation of CDK5
  842. CDK5 functions as a tumor promoter in human lung cancer
  843. (S)-Lacosamide binding to collapsin response mediator protein 2 (CRMP2) regulates CaV2. 2 activity by subverting its phosphorylation by CDK5
  844. CDK5 is a major regulator of the tumor suppressor DLC1
  845. Reduction of ciliary length through pharmacologic or genetic inhibition of CDK5 attenuates polycystic kidney disease in a model of nephronophthisis
  846. Inhibition of CDK5 promotes β-cell differentiation from ductal progenitors
  847. PARP Inhibition Suppresses GR–MYCN–CDK5 –RB1–E2F1 Signaling and Neuroendocrine Differentiation in Castration-Resistant Prostate CancerPARP Inhibition …
  848. Phloretin and phloridzin improve insulin sensitivity and enhance glucose uptake by subverting PPARγ/CDK5 interaction in differentiated adipocytes
  849. CDK5 increases MARK4 activity and augments pathological tau accumulation and toxicity through tau phosphorylation at Ser262
  850. The serotonin 6 receptor controls neuronal migration during corticogenesis via a ligand-independent CDK5 -dependent mechanism
  851. TNF-α increases production of reactive oxygen species through CDK5 activation in nociceptive neurons
  852. Curcumin downregulates GSK3 and CDK5 in scopolamine-induced Alzheimer’s disease rats abrogating Aβ 40/42 and tau hyperphosphorylation
  853. Amyloid-ß promotes neurotoxicity by CDK5 -induced p53 stabilization
  854. CDK5 controls lymphatic vessel development and function by phosphorylation of Foxc2
  855. The BRCC3 regulated by CDK5 promotes the activation of neuronal NLRP3 inflammasome in Parkinson’s disease models
  856. CDK5 regulation of the GRAB-mediated Rab8-Rab11 cascade in axon outgrowth
  857. CDK5 -mediated phosphorylation and autophagy of RKIP regulate neuronal death in Parkinson’s disease
  858. Sex-specific regulation of fear memory by targeted epigenetic editing of CDK5
  859. The role of CDK5 ‐mediated Drp1 phosphorylation in Aβ1‐42 induced mitochondrial fission and neuronal apoptosis
  860. Peptide TFP5/TP5 derived from CDK5 activator P35 provides neuroprotection in the MPTP model of Parkinson’s disease
  861. Computational simulations identified two candidate inhibitors of CDK5 /p25 to abrogate tau-associated neurological disorders
  862. … RNA MALAT1 and its target microRNA-125b are potential biomarkers for Alzheimer’s disease management via interactions with FOXQ1, PTGS2 and CDK5
  863. CDK5 in oncology: recent advances and future prospects
  864. An immunohistochemical study of cyclin-dependent kinase 5 (CDK5 ) expression in non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC): a …
  865. CDK5 -mediated Drp1 phosphorylation drives mitochondrial defects and neuronal apoptosis in radiation-induced optic neuropathy
  866. Cyclin-dependent kinase 5 (CDK5 ) regulates the circadian clock
  867. Site-specific phosphorylation of Fbxw7 by CDK5 /p25 and its resulting decreased stability are linked to glutamate-induced excitotoxicity
  868. The driving role of the CDK5 /Tln1/FAKS732 axis in cancer cell extravasation dissected by human vascularized microfluidic models
  869. CDK5 -dependent Mst3 phosphorylation and activity regulate neuronal migration through RhoA inhibition
  870. ERK MAP kinase activation in spinal cord regulates phosphorylation of CDK5 at serine 159 and contributes to peripheral inflammation induced pain …
  871. CDK5 inhibition abrogates TNBC stem‐cell property and enhances anti‐PD‐1 therapy
  872. Calcium dysregulation and CDK5 -ATM pathway involved in a mouse model of fragile X-associated tremor/ataxia syndrome
  873. CDK5 -mediated CRMP2 phosphorylation is necessary and sufficient for peripheral neuropathic pain
  874. CDK5 /p35 functions as a crucial regulator of spatial learning and memory
  875. CDK5 inhibition resolves PKA/cAMP-independent activation of CREB1 signaling in glioma stem cells
  876. CDK5 ‐dependent activation of dynein in the axon initial segment regulates polarized cargo transport in neurons
  877. Searching for Novel CDK5 Substrates in Brain by Comparative Phosphoproteomics of Wild Type and CDK5 −/− Mice
  878. Identification and comparison of plant-derived scaffolds as selective CDK5 inhibitors against standard molecules: Insights from umbrella sampling simulations
  879. Enhancement of BACE1 activity by p25/CDK5 -mediated phosphorylation in Alzheimer’s disease
  880. Future aspects of CDK5 in prostate cancer: from pathogenesis to therapeutic implications
  881. CDK5 links with DNA damage response and cancer
  882. Long-and short-term CDK5 knockdown prevents spatial memory dysfunction and tau pathology of triple transgenic Alzheimer’s mice
  883. Cyclin I and p35 determine the subcellular distribution of CDK5
  884. CDK5 promotes DNA replication stress checkpoint activation through RPA-32 phosphorylation, and impacts on metastasis free survival in breast cancer patients
  885. CDK5 regulates paclitaxel sensitivity in ovarian cancer cells by modulating AKT activation, p21Cip1-and p27Kip1-mediated G1 cell cycle arrest and apoptosis
  886. Roscovitine, a CDK5 inhibitor, alleviates sevoflurane-induced cognitive dysfunction via regulation Tau/GSK3β and ERK/PPARγ/CREB signaling
  887. CDK5 regulates activity-dependent gene expression and dendrite development
  888. Tamoxifen inhibits CDK5 kinase activity by interacting with p35/p25 and modulates the pattern of tau phosphorylation
  889. Cyclin I-like (CCNI2) is a cyclin-dependent kinase 5 (CDK5 ) activator and is involved in cell cycle regulation
  890. TFP5, a peptide derived from p35, a CDK5 neuronal activator, rescues cortical neurons from glucose toxicity
  891. Discovery of thienoquinolone derivatives as selective and ATP non-competitive CDK5 /p25 inhibitors by structure-based virtual screening
  892. TFP5, a peptide inhibitor of aberrant and hyperactive CDK5 /p25, attenuates pathological phenotypes and restores synaptic function in CK-p25Tg mice
  893. CDK5 inhibitors prevent astroglial apoptosis and reactive astrogliosis by regulating PKA and DRP1 phosphorylations in the rat hippocampus
  894. ARNTL hypermethylation promotes tumorigenesis and inhibits cisplatin sensitivity by activating CDK5 transcription in nasopharyngeal carcinoma
  895. Hyperactive innate immunity causes degeneration of dopamine neurons upon altering activity of CDK5
  896. The atypical cyclin-dependent kinase 5 (CDK5 ) guards podocytes from apoptosis in glomerular disease while being dispensable for podocyte development
  897. p47Phox/CDK5 /DRP1-mediated mitochondrial fission evokes PV cell degeneration in the rat dentate gyrus following status epilepticus
  898. Both GSK-3β/CRMP2 and CDK5 /CRMP2 pathways participate in the protection of dexmedetomidine against propofol-induced learning and memory impairment in …
  899. Three decades of CDK5
  900. CDK5 suppression blocks SIRT1 degradation via the ubiquitin-proteasome pathway in Parkinson’s disease models
  901. Differential expression of cell cycle regulators in CDK5 -dependent medullary thyroid carcinoma tumorigenesis
  902. Melatonin ameliorates tau-related pathology via the miR-504-3p and CDK5 axis in Alzheimer’s disease
  903. Inhibition of CDK5 induces cell death of tumor-initiating cells
  904. p39 is responsible for increasing CDK5 activity during postnatal neuron differentiation and governs neuronal network formation and epileptic responses
  905. CDK5 knockdown in astrocytes provide neuroprotection as a trophic source via Rac1
  906. DYRK1A negatively regulates CDK5 -SOX2 pathway and self-renewal of glioblastoma stem cells
  907. Phosphorylation of CRMP2 by CDK5 regulates dendritic spine development of cortical neuron in the mouse hippocampus
  908. The peptide-directed lysosomal degradation of CDK5 exerts therapeutic effects against stroke
  909. CDK5 -mediated tau accumulation triggers methamphetamine-induced neuronal apoptosis via endoplasmic reticulum-associated degradation pathway
  910. Deletion of CDK5 in Macrophages Ameliorates Anti-Inflammatory Response during Endotoxemia through Induction of C-Maf and Il-10
  911. … persistent chronic stress-induced behavioral deficits that are associated with prefrontal cortex activation of the p25/CDK5 -glucocorticoid receptor pathway
  912. CDK5 -mediated mitochondrial fission: a key player in dopaminergic toxicity in Huntington’s disease
  913. Cyclin I promotes cisplatin resistance via CDK5 activation in cervical cancer
  914. Fluorescent biosensor of CDK5 kinase activity in glioblastoma cell extracts and living cells
  915. CDK5 inhibitor roscovitine alleviates neuropathic pain in the dorsal root ganglia by downregulating N-methyl-D-aspartate receptor subunit 2A
  916. Cyclin-dependent kinase 5 (CDK5 ) controls melanoma cell motility, invasiveness, and metastatic spread—identification of a promising novel therapeutic target
  917. Adhesion GPCR latrophilin-2 specifies cardiac lineage commitment through CDK5 , Src, and P38MAPK
  918. LRRK2 facilitates tau phosphorylation through strong interaction with tau and CDK5
  919. Cdk12 and Cdk13 regulate axonal elongation through a common signaling pathway that modulates CDK5 expression
  920. p39-associated CDK5 activity regulates dendritic morphogenesis
  921. Synthesis and optimization of an original V-shaped collection of 4-7-disubstituted Pyrido [3, 2-d] pyrimidines as CDK5 and DYRK1A inhibitors
  922. CDK5 -mediated phosphorylation of Sirt1 contributes to podocyte mitochondrial dysfunction in diabetic nephropathy
  923. CDK5 -mediated inhibition of APC/C-Cdh1 switches on the cyclin D1-Cdk4-pRb pathway causing aberrant S-phase entry of postmitotic neurons
  924. Proteomic analysis of the human cyclin-dependent kinase family reveals a novel CDK5 complex involved in cell growth and migration
  925. Phosphorylation of p53 by CDK5 contributes to benzo [a] pyrene‐induced neuronal apoptosis
  926. Myricetin prevents thapsigargin-induced CDK5 -P66Shc signalosome mediated pancreatic β-cell dysfunction
  927. Nestin selectively facilitates the phosphorylation of the Lissencephaly-linked protein doublecortin (DCX) by CDK5 /p35 to regulate growth cone morphology and …
  928. CDK5 inhibitor downregulates Mcl-1 and sensitizes pancreatic cancer cell lines to navitoclax
  929. The CDK5 -Mcl-1 axis promotes mitochondrial dysfunction and neurodegeneration in a model of Alzheimer’s disease
  930. S-nitrosylation-dependent proteasomal degradation restrains CDK5 activity to regulate hippocampal synaptic strength
  931. The roles of CDK5 -mediated subcellular localization of FOXO1 in neuronal death
  932. The early synthesis of p35 and activation of CDK5 in LPS-stimulated macrophages suppresses interleukin-10 production
  933. CDK5 activates hippo signaling to confer resistance to radiation therapy via upregulating TAZ in lung cancer
  934. … effects of phosphocreatine on Amyloid Beta 25–35-induced differentiated neuronal cell death through inhibition of AKT/GSK-3β/Tau/APP/CDK5 pathways in vivo and …
  935. Parkinson-related LRRK2 mutation R1628P enables CDK5 phosphorylation of LRRK2 and upregulates its kinase activity
  936. Phosphorylation of CHIP at Ser20 by CDK5 promotes tAIF-mediated neuronal death
  937. The BDNF/TrkB signaling pathway is involved in heat hyperalgesia mediated by CDK5 in rats
  938. Stress-induced CDK5 activity enhances cytoprotective basal autophagy in Drosophila melanogaster by phosphorylating acinus at serine437
  939. Quercetin inhibits okadaic acid-induced tau protein hyperphosphorylation through the Ca2+‑calpain‑p25‑CDK5 pathway in HT22 cells
  940. Abnormal mitochondria in a non-human primate model of MPTP-induced Parkinson’s disease: Drp1 and CDK5 /p25 signaling
  941. A mitotic CDK5 -PP4 phospho-signaling cascade primes 53BP1 for DNA repair in G1
  942. CDK5 downregulation enhances synaptic plasticity
  943. Tumor expression of cyclin-dependent kinase 5 (CDK5 ) is a prognostic biomarker and predicts outcome of oxaliplatin-treated metastatic colorectal cancer patients
  944. APOE4 induces site-specific tau phosphorylation through calpain-CDK5 signaling pathway in EFAD-Tg mice
  945. Role of CDK5 in amyloid-beta pathology of Alzheimer’s disease
  946. Identification of the first PPARα/γ dual agonist able to bind to canonical and alternative sites of PPARγ and to inhibit its CDK5 -mediated phosphorylation
  947. Discovery of CDK5 inhibitors through structure-guided approach
  948. CDK5 and GSK3β inhibit fast endophilin-mediated endocytosis
  949. CDK5 contributes to neuronal apoptosis via promoting MEF2D phosphorylation in rat model of intracerebral hemorrhage
  950. PKA and CDK5 can phosphorylate specific serines on the intracellular domain of podoplanin (PDPN) to inhibit cell motility
  951. Multifaceted regulation of ALDH1A1 by CDK5 in Alzheimer’s disease pathogenesis
  952. Inhibition of CDK5 alleviates the cardiac phenotypes in Timothy syndrome
  953. Two degradation pathways of the p35 CDK5 (Cyclin-dependent Kinase) activation subunit, dependent and independent of ubiquitination
  954. L5-6 Spinal Nerve Ligation-induced Neuropathy Changes the Location and Function of Ca2+ Channels and CDK5 and Affects the Compound Action Potential in …
  955. Epigenetic upregulation of CDK5 in the dorsal horn contributes to neuropathic pain in rats
  956. Ginsenoside Rb1 improves cognitive impairment induced by insulin resistance through CDK5 /p35-NMDAR-IDE pathway
  957. The role of the drebrin/EB3/CDK5 pathway in dendritic spine plasticity, implications for Alzheimer’s disease
  958. Consensus models for CDK5 inhibitors in silico and their application to inhibitor discovery
  959. CDK5 phosphorylation of ErbB4 is required for tangential migration of cortical interneurons
  960. Neuroprotection induced by transplanted CDK5 knockdown astrocytes in global cerebral ischemic rats
  961. All-trans retinoic acid induces DU145 cell cycle arrest through CDK5 activation
  962. Targeting CDK5 post-stroke provides long-term neuroprotection and rescues synaptic plasticity
  963. Phosphorylation of connexin 43 by CDK5 modulates neuronal migration during embryonic brain development
  964. CDK5 -mediated phosphorylation-dependent ubiquitination and degradation of E3 ubiquitin ligases GP78 accelerates neuronal death in Parkinson’s disease
  965. CDK5 and its activator P35 in normal pituitary and in pituitary adenomas: relationship to VEGF expression
  966. Recovery of neurovascular unit integrity by CDK5 -KD astrocyte transplantation in a global cerebral ischemia model
  967. Low expression of CDK5 and p27 are associated with poor prognosis in patients with gastric cancer
  968. Posterior neocortex-specific regulation of neuronal migration by CEP85L identifies maternal centriole-dependent activation of CDK5
  969. p35 and Rac1 underlie the neuroprotection and cognitive improvement induced by CDK5 silencing
  970. TRPV1 function is modulated by CDK5 -mediated phosphorylation: insights into the molecular mechanism of nociception
  971. … for PPAR non-agonist ligands followed by characterization of a hit, AM-879, with additional no-adipogenic and CDK5 -mediated phosphorylation inhibition …
  972. Exploring the mechanism of PPARγ phosphorylation mediated by CDK5
  973. CDK5 controls IL-2 gene expression via repression of the mSin3a-HDAC complex
  974. High glucose increases CDK5 activity in podocytes via transforming growth factor-β1 signaling pathway
  975. Discovery and Optimization of Highly Selective Inhibitors of CDK5
  976. CDK5 drives formation of heterogeneous pancreatic neuroendocrine tumors
  977. CDK5 suppresses the metastasis of gastric cancer cells by interacting with and regulating PP2A
  978. CDK5 promotes renal tubulointerstitial fibrosis in diabetic nephropathy via ERK1/2/PPARγ pathway
  979. CK1δ activity is modulated by CDK2/E-and CDK5 /p35-mediated phosphorylation
  980. Hypoxia induces HT-22 neuronal cell death via Orai1/CDK5 pathway-mediated Tau hyperphosphorylation
  981. Wnt-5a promotes neural development and differentiation by regulating CDK5 via Ca2+/calpain pathway
  982. CDK5 participates in amyloid-β production by regulating PPARγ phosphorylation in primary rat hippocampal neurons
  983. TFP5 peptide, derived from CDK5 -activating cofactor p35, provides neuroprotection in early-stage of adult ischemic stroke
  984. The role of cyclin dependent kinase 5 (CDK5 ) in neuropathic pain
  985. CDK5 contributes to inflammation-induced thermal hyperalgesia mediated by the p38 MAPK pathway in microglia
  986. CDK5 : a key player at neuronal synapse with diverse functions
  987. CDK5 neutralizes the tumor suppressing effect of BIN1 via mediating phosphorylation of c-MYC at Ser-62 site in NSCLC
  988. Synapsin III acts downstream of semaphorin 3A/CDK5 signaling to regulate radial migration and orientation of pyramidal neurons in vivo
  989. Physical Interaction between Cyclin-Dependent Kinase 5 (CDK5 ) and Clock Factors Affects the Circadian Rhythmicity in Peripheral Oscillators
  990. The O-GlcNAc modification of CDK5 involved in neuronal apoptosis following in vitro intracerebral hemorrhage
  991. Phosphorylation of STAT3 by axonal CDK5 promotes axonal regeneration by modulating mitochondrial activity
  992. Generation of the CDK5 activator p25 is a memory mechanism that is affected in early Alzheimer’s disease
  993. Differential regulation of collapsin response mediator protein 2 (CRMP2) phosphorylation by GSK3ss and CDK5 following traumatic brain injury
  994. CDK4 and CDK5 inhibition have comparable mild hypothermia effects in preventing Drp1-dependent mitochondrial fission and neuron death induced by MPP+
  995. CDK5 -mediated JIP1 phosphorylation regulates axonal outgrowth through Notch1 inhibition
  996. CDK5 inhibitory peptide prevents loss of dopaminergic neurons and alleviates behavioral changes in an MPTP induced Parkinson’s disease mouse model
  997. Valproic acid increases NO production via the SH-PTP1–CDK5 –eNOS-Ser116 signaling cascade in endothelial cells and mice
  998. CDK5 inhibition in vitro and in vivo induces cell death in myeloma and overcomes the obstacle of bortezomib resistance
  999. Colocalization of phosphorylated forms of WAVE1, CRMP2, and tau in Alzheimer’s disease model mice: involvement of CDK5 phosphorylation and the effect of ATRA …
  1000. CDK5 positively regulates Notch1 signaling in pancreatic cancer cells by phosphorylation
  1001. CDK5 -mediated phosphorylation of Sirt2 contributes to depressive-like behavior induced by social defeat stress
  1002. CDK5 phosphorylation of STAT3 in dorsal root ganglion neurons is involved in promoting axonal regeneration after peripheral nerve injury
  1003. CDK5 targeting as a therapy for recovering neurovascular unit integrity in Alzheimer’s disease
  1004. Learning impairments, memory deficits, and neuropathology in aged tau transgenic mice are dependent on leukotrienes biosynthesis: role of the CDK5 kinase pathway
  1005. Downregulation of CDK5 restores sevoflurane-induced cognitive dysfunction by promoting SIRT1-mediated autophagy
  1006. Exploring structural requirements of leads for improving activity and selectivity against CDK5 /p25 in Alzheimer’s disease: an in silico approach
  1007. Targeting MicroRNA-125b promotes neurite outgrowth but represses cell apoptosis and inflammation via Blocking PTGS2 and CDK5 in a FOXQ1-dependent …
  1008. O-GlcNAc transferase regulates glioblastoma acetate metabolism via regulation of CDK5 -dependent ACSS2 phosphorylation
  1009. Adeno‐associated virus 9–mediated CDK5 inhibitory peptide reverses pathologic changes and behavioral deficits in the Alzheimer’s disease mouse model
  1010. Phosphorylation by PKA and CDK5 mediates the early effects of synapsin III in neuronal morphological maturation
  1011. Crocin improves insulin sensitivity and ameliorates adiposity by regulating AMPK-CDK5 -PPARγ signaling
  1012. Phosphorylation of Tet3 by CDK5 is critical for robust activation of BRN2 during neuronal differentiation
  1013. Ubiquitin ligase activity inhibits CDK5 to control axon termination
  1014. Suppressing CDK5 Activity by Luteolin Inhibits MPP+-Induced Apoptotic of Neuroblastoma through Erk/Drp1 and Fak/Akt/GSK3β Pathways
  1015. Targeting CDK5 in Astrocytes Promotes Calcium Homeostasis Under Excitotoxic Conditions
  1016. CDK5 -mediated phosphorylation of XBP1s contributes to its nuclear translocation and activation in MPP+-induced Parkinson’s disease model
  1017. Stress-induced nuclear translocation of CDK5 suppresses neuronal death by downregulating ERK activation via VRK3 phosphorylation
  1018. Diabetes-induced H3K9 hyperacetylation promotes development of Alzheimer’s disease through CDK5
  1019. CDK5 -dependent phosphorylation of liprinα1 mediates neuronal activity-dependent synapse development
  1020. Roles of Id1/HIF-1 and CDK5 /HIF-1 in cell cycle reentry induced by amyloid-beta peptide in post-mitotic cortical neuron
  1021. CDK5 inhibits the clathrin-dependent internalization of TRPV1 by phosphorylating the clathrin adaptor protein AP2μ2
  1022. Cyclin-dependent kinase 5 (CDK5 )-dependent phosphorylation of p70 ribosomal S6 kinase 1 (S6K) is required for dendritic spine morphogenesis
  1023. CDK5 phosphorylation-induced SIRT2 nuclear translocation promotes the death of dopaminergic neurons in Parkinson’s disease
  1024. Differential expression of CDK5 -phosphorylated CRMP2 following a spared nerve injury
  1025. CK2 inhibition confers functional protection to young and aging axons against ischemia by differentially regulating the CDK5 and AKT signaling pathways
  1026. RET regulates human medullary thyroid cancer cell proliferation through CDK5 and STAT3 activation
  1027. Roscovitine, an experimental CDK5 inhibitor, causes delayed suppression of microglial, but not astroglial recruitment around intracerebral dopaminergic grafts
  1028. Neuregulin-1β plays a neuroprotective role by inhibiting the CDK5 signaling pathway after cerebral ischemia-reperfusion injury in rats
  1029. Characterization of the CDK5 gene in Apis cerana cerana (AccCDK5 ) and a preliminary identification of its activator gene, AccCDK5 r1
  1030. CB1R regulates CDK5 signaling and epigenetically controls Rac1 expression contributing to neurobehavioral abnormalities in mice postnatally exposed to ethanol
  1031. CDK5 deletion enhances the anti-inflammatory potential of GC-mediated GR activation during inflammation
  1032. Quantitative Phosphoproteomic analysis in alpha-Synuclein transgenic mice reveals the involvement of aberrant p25/CDK5 signaling in early-stage Parkinson’s …
  1033. Dissociative role for dorsal hippocampus in mediating heroin self‐administration and relapse through CDK5 and RhoB signaling revealed by proteomic analysis
  1034. CDK5 is required for the neuroprotective effect of transforming growth factor-β1 against cerebral ischemia-reperfusion
  1035. Protocols for Characterization of CDK5 Kinase Activity
  1036. Prenatal bisphenol A exposure contributes to Tau pathology: Potential roles of CDK5 /GSK3β/PP2A axis in BPA-induced neurotoxicity
  1037. Heat shock inhibition of CDK5 increases NOXA levels through miR-23a repression
  1038. Tibolone modulates neuronal plasticity through regulating Tau, GSK3β/Akt/PI3K pathway and CDK5 p35/p25 complexes in the hippocampus of aged male …
  1039. Regulation of CRMP2 by CDK5 and GSK-3β participates in sevoflurane-induced dendritic development abnormalities and cognitive dysfunction in developing rats
  1040. Computational Study of the Allosteric Effects of p5 on CDK5 –p25 Hyperactivity as Alternative Inhibitory Mechanisms in Neurodegeneration
  1041. Metformin promotes neuronal differentiation via crosstalk between CDK5 and Sox6 in neuroblastoma cells
  1042. Overexpression of the CDK5 inhibitory peptide in motor neurons rescue of amyotrophic lateral sclerosis phenotype in a mouse model
  1043. Knockdown of expression of CDK5 or p35 (a CDK5 activator) results in podocyte apoptosis
  1044. Cyclic AMP and polyamines overcome inhibition by myelin-associated glycoprotein through eIF5A-mediated increases in p35 expression and activation of CDK5
  1045. CDK5 inhibitory peptide prevents loss of neurons and alleviates behavioral changes in p25 transgenic mice
  1046. CDK5 phosphorylation of EFhd2 at S74 affects its calcium binding activity
  1047. CDK5 contributes to Huntington’s disease learning and memory deficits via modulation of brain region-specific substrates
  1048. Opiate exposure state controls dopamine D3 receptor and CDK5 /calcineurin signaling in the basolateral amygdala during reward and withdrawal aversion memory …
  1049. Oligodendrocyte-specific loss of CDK5 disrupts the architecture of nodes of Ranvier as well as learning and memory
  1050. Involvement of CDK5 activating subunit p35 in synaptic plasticity in excitatory and inhibitory neurons
  1051. The CDK5 activator P39 specifically links muskelin to myosin II and regulates stress fiber formation and actin organization in lens
  1052. Designing of dual inhibitors for GSK-3β and CDK5 : Virtual screening and in vitro biological activities study
  1053. Molecular recognition of PPARγ by kinase CDK5 /p25: Insights from a combination of protein–protein docking and adaptive biasing force simulations
  1054. Three-dimensional structural analysis reveals a CDK5 -mediated kinase cascade regulating hepatic biliary network branching in zebrafish
  1055. PTPN21 protects PC12 cell against oxygen-glucose deprivation by activating CDK5 through ERK1/2 signaling pathway
  1056. The CDK5 inhibitor Roscovitine increases LTP induction in corticostriatal synapses
  1057. Two-hour acute restraint stress facilitates escape behavior and learning outcomes through the activation of the CDK5 /GR P S211 pathway in male mice
  1058. Discovery by Virtual Screening of an Inhibitor of CDK5 -Mediated PPARγ Phosphorylation
  1059. Streptozotocin Induces Alzheimer’s Disease-Like Pathology in Hippocampal Neuronal Cells via CDK5 /Drp1-Mediated Mitochondrial Fragmentation
  1060. Functional characterization of CDK5 and CDK5 R1 mutations identified in patients with non-syndromic intellectual disability
  1061. Phosphorylation of CRMP2 by CDK5 negatively regulates the surface delivery and synaptic function of AMPA receptors
  1062. TP5, a peptide inhibitor of aberrant and hyperactive CDK5 /p25: A novel therapeutic approach against glioblastoma
  1063. CDK5 phosphorylates CaV1. 3 channels and regulates GABAA-mediated miniature inhibitory post-synaptic currents in striato-nigral terminals
  1064. Regulation of in vivo dynein force production by CDK5 and 14-3-3ε and KIAA0528
  1065. Modulation of TRPA1 channel activity by CDK5 in sensory neurons
  1066. CDK5 is essential for amphetamine to increase dendritic spine density in hippocampal pyramidal neurons
  1067. Regional specific activations of ERK1/2 and CDK5 differently regulate astroglial responses to ER stress in the rat hippocampus following status epilepticus
  1068. Calpain-2/p35-p25/CDK5 pathway is involved in the neuronal apoptosis induced by polybrominated diphenyl ether-153
  1069. Novel optimization of valmerins (tetrahydropyrido [1, 2-a] isoindolones) as potent dual CDK5 /GSK3 inhibitors
  1070. Targeting CDK5 for killing of breast cancer cells via perturbation of redox homeostasis
  1071. Estrogen improved the regeneration of axons after subcortical axon injury via regulation of PI3K/Akt/CDK5 /Tau pathway
  1072. Role of CDK5 in Kalirin7-mediated formation of dendritic spines
  1073. Dendritic distribution of CDK5 mRNA and p35 mRNA, and a glutamate-responsive increase of CDK5 /p25 complex contribute to tau hyperphosphorylation
  1074. Inhibition of CDK5 rejuvenates inhibitory circuits and restores experience-dependent plasticity in adult visual cortex
  1075. AAV9-mediated CDK5 inhibitory peptide reduces hyperphosphorylated tau and inflammation and ameliorates behavioral changes caused by overexpression of p25 in …
  1076. CDK5 -mediated phosphorylation of p19INK4d avoids DNA damage-induced neurodegeneration in mouse hippocampus and prevents loss of cognitive …
  1077. Downregulation of CDK5 signaling in the dorsal striatum alters striatal microcircuits implicating the association of pathologies with circadian behavior in mice
  1078. Loss of CDK5 function in the nucleus accumbens decreases wheel running and may mediate age‐related declines in voluntary physical activity
  1079. Olfactory deprivation hastens Alzheimer-like pathologies in a human tau-overexpressed mouse model via activation of CDK5
  1080. CDK5 Knockdown inhibits proliferation and induces apoptosis and Cell Cycle Arrest in Human Glioblastoma
  1081. Inhibition of CDK5 in PV Neurons Reactivates Experience-Dependent Plasticity in Adult Visual Cortex
  1082. Inhibition of CDK5 Ameliorates Skeletal Bone Loss in Glucocorticoid-Treated Mice
  1083. Altered expression of the CDK5 activator-like protein, CDK5 α, causes neurodegeneration, in part by accelerating the rate of aging
  1084. Valproic acid downregulates CDK5 activity via the transcription of the p35 mRNA
  1085. CDK5 regulatory subunit-associated protein 1-like 1 negatively regulates adipocyte differentiation through activation of Wnt signaling pathway
  1086. Preferential targeting of p39-activated CDK5 to Rac1-induced lamellipodia
  1087. Interaction of CDK5 and cAMP/PKA signaling in the mediation of neuropsychiatric and neurodegenerative diseases
  1088. The S. pombe CDK5 ortholog Pef1 regulates sexual differentiation through control of the TORC1 pathway and autophagy
  1089. Vps35 deficiency impairs CDK5 /p35 degradation and promotes the hyperphosphorylation of tau protein in retinal ganglion cells
  1090. CDK5 ‐mediated phosphorylation regulates phosphatidylinositol 4‐phosphate 5‐kinase type I γ 90 activity and cell invasion
  1091. In vivo analysis of the phosphorylation of tau and the tau protein kinases CDK5 -p35 and GSK3β by using Phos-tag SDS–PAGE
  1092. Suppression of neuroinflammation in forebrain-specific CDK5 conditional knockout mice by PPARγ agonist improves neuronal loss and early lethality
  1093. Effects of Single-Dose and Long-Term Ketamine Administration on Tau Phosphorylation–Related Enzymes GSK-3β, CDK5 , PP2A, and PP2B in the Mouse …
  1094. CDK5 regulatory subunit-associated protein 1 knockout mice show hearing loss phenotypically similar to age-related hearing loss
  1095. CDK5 -mediated Acn/Acinus phosphorylation regulates basal autophagy independently of metabolic stress
  1096. CDK5 inhibition improves glucose uptake in insulin‐resistant neuronal cells via ERK1/2 pathway
  1097. Lnc-ATG9B-4 aggravates progress of hepatocellular carcinoma through cell proliferation and migration by upregulating CDK5
  1098. Valproic Acid-Induced Anxiety and Depression Behaviors are Ameliorated in p39 CDK5 Activator-Deficient Mice
  1099. Low p-SYN1 (Ser-553) Expression Leads to Abnormal Neurotransmitter Release of GABA Induced by Up-Regulated CDK5 after Microwave Exposure: Insights …
  1100. Computational simulations identify pyrrolidine-2, 3-dione derivatives as novel inhibitors of CDK5 /p25 complex to attenuate Alzheimer’s pathology
  1101. Deficiency of Parkinson’s Related Protein DJ-1 Alters CDK5 Signalling and Induces Neuronal Death by Aberrant Cell Cycle Re-entry
  1102. CDK5 /p25 specific inhibitory peptide TFP5 rescues the loss of dopaminergic neurons in a sub-acute MPTP induced PD mouse model
  1103. Epigenetic control of CDK5 promoter regulates diabetes-associated development of Alzheimer’s disease
  1104. Tissue-type plasminogen activator regulates p35-mediated CDK5 activation in the postsynaptic terminal
  1105. Inactivated AMPK-α2 promotes the progression of diabetic brain damage by CDK5 phosphorylation at Thr485 site
  1106. Overexpression of CDK5 in neural stem cells facilitates maturation of embryonic neurocytes derived from rats in vitro
  1107. Clozapine induces chloride channel-4 expression through PKA activation and modulates CDK5 expression in SH-SY5Y and U87 cells
  1108. Studying nestin and its interrelationship with CDK5
  1109. Tfh Exosomes Derived from Allergic Rhinitis Promote DC Maturation Through miR-142-5p/CDK5 /STAT3 Pathway
  1110. Prenatal alcohol exposure alters p35, CDK5 and GSK3β in the medial frontal cortex and hippocampus of adolescent mice
  1111. CDK5 Regulatory Subunit-Associated Protein 1-Like 1 Gene Polymorphisms and Gestational Diabetes Mellitus Risk: A Trial Sequential Meta-Analysis of …
  1112. … profiled 3-ethoxycarbonyl-1-aza-9-oxafluorenes representing a perspective compound class targeting Alzheimer disease relevant kinases CDK1, CDK5 and GSK-3β
  1113. Regulation of growth hormone biosynthesis by CDK5 regulatory subunit associated protein 1-like 1 (CDKAL1) in pituitary adenomas
  1114. MultiBacMam Bimolecular Fluorescence Complementation (BiFC) tool-kit identifies new small-molecule inhibitors of the CDK5 -p25 protein-protein interaction …
  1115. Computational study of the inhibitory mechanism of the kinase CDK5 hyperactivity by peptide p5 and derivation of a pharmacophore
  1116. CDK5 /NFAT5-Regulated Transporters Involved in Osmoregulation in Fejervarya cancrivora
  1117. Nociceptive signaling through TRPV1 is regulated by CDK5 -mediated phosphorylation of T407 in vivo
  1118. The S. pombe CDK5 Orthologue Pef1 Cooperates with Three Cyclins, Clg1, Pas1 and Psl1, to Promote Pre-Meiotic DNA Replication
  1119. Visualization of trigeminal ganglion sensory neuronal signaling regulated by CDK5
  1120. The HU177 collagen epitope controls melanoma cell migration and experimental metastasis by a CDK5 /YAP-dependent mechanism
  1121. The LPA-CDK5 -tau pathway mediates neuronal injury in an in vitro model of ischemia-reperfusion insult
  1122. A cyclin-dependent kinase 5-derived peptide inhibits CDK5 /p25 activity and improves neurodegenerative phenotypes
  1123. VGLUT2/CDK5 /p25 signaling pathway contributed to inflammatory pain by complete Freund’s adjuvant
  1124. CDK5 regulates developmental remodeling of mushroom body neurons in Drosophila
  1125. Mechanism of CDK5 -synaptophysin-SNARE pathway in acute and chronic inflammatory pain
  1126. CDK5 and MAPT gene expression in Alzheimer’s disease brain samples
  1127. Prognostic significance of the CDK5 gene in breast cancer: an in silico study
  1128. Profiling of p5, a 24 amino acid inhibitory peptide derived from the CDK5 activator, p35 CDKR1 against 70 protein kinases
  1129. CDK5 Mediates Proinflammatory Effects of Microglia through Activated DRP1 Phosphorylation in Rat Model of Intracerebral Hemorrhage
  1130. Long non-coding RNA expression profile in CDK5 -knockdown mouse skin
  1131. Role of CDK5 /cyclin complexes in ischemia-induced death and survival of renal tubular cells
  1132. CSIG-24. TARGETED INHIBITION OF CDK5 -MEDIATED REGULATION OF HUMAN ENDOGENOUS RETROVIRUS K (HML-2) ENVELOPE PROTEIN IN ATYPICAL …
  1133. Association between the expression of amphetamine-induced behavioral sensitization and CDK5 /p35 activity in dorsal striatum.
  1134. Differential regulation of excitatory synaptic transmission in the hippocampus and anterior temporal lobe by cyclin dependent kinase 5 (CDK5 ) in mesial temporal lobe …
  1135. LMW cyclin E and its novel catalytic partner CDK5 are therapeutic targets and prognostic biomarkers in salivary gland cancers
  1136. Changes in the prefrontal cortex after the hippocampus was injected with Aβ25-35 via the P35/P25-CDK5 -Tau hyperphosphorylation signaling pathway
  1137. Decreased synapse‐associated proteins are associated with the onset of epileptic memory impairment in endothelial CDK5 ‐deficient mice
  1138. Potential mechanisms underlying CDK5 related Osteosarcoma progression
  1139. Over-expression of CDK5 in human endometrial cancer.
  1140. CDK3, CDK5 and CDK8 Proteins as Prognostic and Potential Biomarkers in Colorectal Cancer Patients
  1141. Protective effect of valproic acid on MPP+-induced neurotoxicity in dopaminergic SH-SY5Y cells through CDK5 /p35/Erk signaling cascade
  1142. Inhibition of the CDK5 /caspase-3 Pathway by p5-TAT Protects Hippocampal Neurogenesis and Alleviates Radiation-induced Cognitive Dysfunction
  1143. Effects of arsenic poisoning on neuronal cell apoptosis and mRNA and protein expression of calpain 1, calpain 2, and CDK5 /p25
  1144. CDK5 Regulates PD-L1 expression and cell maturation in dendritic cells of CRSwNP
  1145. Therapeutic effects of TP5, a CDK5 /p25 inhibitor, in in vitro and in vivo models of Parkinson’s disease
  1146. Amyloid-β fosters p35/CDK5 signaling contributing to changes of inhibitory synapses in early stages of cerebral amyloidosis
  1147. CDK5 inhibition protects against OGDR induced mitochondrial fragmentation and apoptosis through regulation of Drp1S616 phosphorylation
  1148. … transient protein-protein interactions that regulate the activity of human lemur tyrosine kinase-3 (LMTK3) domain by cyclin dependent kinase 5 (CDK5 ) in breast cancer …
  1149. Identification and Verification of the Ability of CDK5 to Phosphorylate Deubiquitinating Enzyme BRCC3 In Vitro
  1150. Microtubule plus-end tracking of end-binding protein 1 (EB1) is regulated by CDK5 regulatory subunit-associated protein 2
  1151. Endothelium-derived CDK5 deficit aggravates air pollution-induced peripheral vasoconstriction through AT1R upregulation
  1152. Extracellular CIRP Activates the IL-6Rα/STAT3/CDK5 Pathway in Neurons
  1153. Influence of CDK5 Regulatory Subunit-Associated Protein 1-Like 1 Expression on the Survival of Patients with Non-Metastatic Nasopharyngeal Carcinoma
  1154. THE EFFECT OF ENDURANCE TRAINING ON GENE EXPRESSION OF CDK5 IN SPINAL MOTOR PART OF MALE WISTAR RATS WITH DIABETIC NEUROPATHY
  1155. Binding mechanism of CDK5 with roscovitine derivatives based on molecular dynamics simulations and MM/PBSA methods
  1156. CDK5 and Foxc2–a new relationship in the lymphatic vasculature
  1157. Active CDK5 immunoprecipitation and kinase assay
  1158. Study of ATM phosphorylation by CDK5 in neuronal cells
  1159. Correction: Corrigendum: Deactivation of excitatory neurons in the prelimbic cortex via CDK5 promotes pain sensation and anxiety
  1160. Induction of CRMP‐2 phosphorylation by CDK5 restricts the repair of damaged optic nerve
  1161. … –assisted Function X (PIMAX) Approach to Producing Challenging Proteins Including Hyperphosphorylated Tau and Active CDK5 /p25 Kinase Complex
  1162. Regulation of thin recipe of Buyang Huanwudecoction on CDK5 expression of rats after cerebral ischemia
  1163. Analysis of the inhibitory elements in the p5 peptide fragment of the CDK5 activator, p35, CDKR1 protein
  1164. The importance of regulatory role of panaxoside Rg1 in CDK5 on hippocampal neuron radioactive damage protection
  1165. CDK5 inhibition promotes osteoblastic differentiation of MSCs and blocks the migration of osteosarcoma MG-63 cells
  1166. MiR-26a regulated adipogenic differentiation of ADSCs induced by insulin through CDK5 /FOXC2 pathway
  1167. Investigating the Role of CDK5 in Alzheimer’s Disease and Type‐2 Diabetes
  1168. CDK5 regulates N-cadherin-dependent neuronal migration during cortical development
  1169. Post-translational modifications of CDK5 and their biological roles in cancer
  1170. Mesenchymal stem cells loaded with p5, derived from CDK5 activator p35, inhibit calcium-induced CDK5 activation in endothelial cells
  1171. Motor learning and long‐term plasticity of parallel fibre‐Purkinje cell synapses require post‐synaptic CDK5 /p35
  1172. Development of an ELISA for High-Throughput Screening of Inhibitors of CDK5 -Mediated PPARγ Phosphorylation
  1173. Regulation on intercross effect between CDK5 mediated apoptosis and autophagy after cerebral ischemia
  1174. Inhibition of CDK5 in colorectal cancer
  1175. Lipopolysaccharide-induced inflammation in human peritoneal mesothelial cells is controlled by ERK1/2-CDK5 -PPARγ axis
  1176. Effects of p35 mutations associated with mental retardation on the cellular function of p35-CDK5
  1177. Restoration of CDK5 , TrkB and soluble N-ethylmaleimide-sensitive factor attachment protein receptor proteins after chronic methylphenidate treatment in …
  1178. Analysis of CDK5 -related phosphoproteomics in growth cones
  1179. Pooled shRNA screening using mouse xenografts of human hepatocellular carcinoma cells identifies CDK5 as a potential mechanism mediating sorafenib resistance
  1180. Neurogenesis and gliogenesis modulation in cerebral ischemia by CDK5 RNAi-based therapy
  1181. CDK5 is required for the positioning and survival of GABAergic neurons in developing mouse striatum
  1182. Progress on Correlation between the Expression of CDK5 and Brain Injury Time
  1183. Synapsin III Controls Early Phases of Dopaminergic Neurons Development in Fishes and Mammals by Acting Upstream of BDNF and CDK5 Signaling
  1184. A rapid and sensitive bioanalytical LC–MS/MS method for the quantitation of a novel CDK5 inhibitor 20–223 (CP668863) in plasma: Application to in vitro metabolism …
  1185. CDK5 activity is required for Purkinje cell dendritic growth in cell‐autonomous and non‐cell‐autonomous manners
  1186. In silico study on the selective inhibition of Alzheimer’s disease (AD) pathological complex CDK5 -p25 by peptide p5 in presence of munc 18 (p67)
  1187. Kinase CDK5 in tumors
  1188. Hyperactive Innate Immunity Causes Degeneration of Dopamine Neurons upon Altering Activity of CDK5
  1189. … reversion to oxaliplatin-acquired resistance in colorectal cancer cell lines through modulation of nuclear factor κB (NFκB) and cyclin-dependent kinase 5 (CDK5 )
  1190. Getting Excited Through Cyclin: A Role for Endothelial CDK5 Signaling in Hippocampal Hyperexcitability
  1191. O-GlcNAc transferase regulates glioblastoma acetate metabolism via regulation of CDK5 -dependent ACSS2 phosphorylation
  1192. CDK5 mediated phosphorylation of cytosolic phospholipase A2 regulates its activity and neuroinflammation in Parkinson’s Disease
  1193. Notch and CDK5 in Zebrafish Mindbomb Mutant: Co-regulation or Coincidence?
  1194. Erratum: Cyclin I-like (CCNI2) is a cyclin-dependent kinase 5 (CDK5 ) activator and is involved in cell cycle regulation
  1195. Quantitative phosphoproteomics reveals regulatory state dependent efficacy of chemical Cdk1 inhibition and distinct CDK5 complexes as novel Wee1 substrates
  1196. Correction to: ARNTL hypermethylation promotes tumorigenesis and inhibits cisplatin sensitivity by activating CDK5 transcription in nasopharyngeal carcinoma
  1197. Downregulation of CDK5 Signaling In the Dorsal Striatum Alters Striatal Microcircuits and Perturbs Circadian Behavior in Mice
  1198. TFP5, a Peptide Derived From CDK5 Activator p35, Protects Pancreatic β-Cells From Glucose Toxicity
  1199. CDK5 and epithelial-mesenchymal transition related proteins are abnormally expressed in head and neck squamous cell carcinoma
  1200. Ameliorating Alzheimer’s-like pathology by Minocycline via inhibiting CDK5 /p25 signaling.
  1201. The S. pombe CDK5 Orthologue Pef1 Cooperates with Three Cyclins, Clg1, Pas1 and Psl1, to Promote Pre-Meiotic DNA Replication. Biomolecules 2021, 11 …
  1202. Lack of CDK5 activity is involved on Dopamine Transporter expression and function: Evidences from an animal model of Attention-Deficit Hyperactivity Disorder
  1203. Differential expression of CDK5 -phosphorylated CRMP2 following a spared nerve injury
  1204. PO-447 CDK5 as a prognostic and predictive factor in colorectal cancer patients
  1205. CDK5 : The Connection Between Alzheimer’s Disease and Type 2 Diabetes?
  1206. Evaluation of CDK5 inhibitors in neural crest tumors
  1207. Correction to: CDK5 regulates PD-L1 expression and cell maturation in dendritic cells of CRSwNP
  1208. A deficitary model of CDK5 does not impairs neuronal differentiation of human pluripotent stem cells
  1209. CDK5 negatively regulates Rho by phosphorylating and activating the Rho-GAP and tumor suppressor functions of DLC1
  1210. The Role of CDK5 in Tumours and Tumour Microenvironments. Cancers 2021, 13, 101
  1211. CDK5 influences the organization of the Circadian Machinery in peripheral clocks.
  1212. A concise review on cyclin dependent kinase 5 (CDK5 ) inhibitors
  1213. Interplay between CDK5 and IRF2BP1 enhances breast cancer brain metastasis
  1214. CDK5 Activation Drives Pancreatic Neuroendocrine Tumorigenesis and is a Therapeutic Target
  1215. Impact of Phosphorylation of CDK5 at Residues Serine 46 and Serine 47 on Its Activity and Function
  1216. EPAC2 knockout causes abnormal tau pathology through calpain-mediated CDK5 activation
  1217. CDK5 -dependent inhibitory phosphorylation of Drp1 during neuronal maturation
  1218. Identification and Verification of CDK5 Phosphorylated Deubiquitinating Enzyme BRCC3
  1219. Potential Benefits of Melatonergic Treatment in Schizophrenia: Ameliorating Demyelination via Inhibiting CDK5 -Mediated Hyper Autophagy
  1220. CDK5 Loss Alters Mitochondrial Cristae Organization
  1221. PTGS2, CD133, CDK5 knockout comparison by CRISPR CAS-9 system in UV-Induced and Metastatic Melanoma
  1222. Characterization of neurochemical activities through inhibition of CDK5 or AChE by dimers of tacrine and neostigmine respectively
  1223. A novel role of CDK5 in tumor growth, migration and proliferation of breast cancer cell lines MDA-MB-231 and BT-474
  1224. CDK5 Inhibitor Seliciclib Promotes Osteoblastic Differentiation of MSCs and Suppresses the Migration of MG-63 Osteosarcoma Cells
  1225. CDK5 /CAMK2-DRP1-AMPK-Mediated Mitochondrial Fission is Required for Imatinib Resistance of CML Cells
  1226. The effect of CDK5 on mitochondrial function in Glioblastoma Multiforme (GBM)
  1227. Functional Characterization of the Interaction Between Alkali Cation/Proton Exchanger SLC9A6/NHE6 and Cyclin Dependent Kinase 5 (CDK5 )
  1228. Seasonal changes in actin and CDK5 expression in different brain regions of the Yakut ground squirrel (Spermophilus undulatus)
  1229. DDIS-27. TARGETING ATP DOCKING AND P35/P25 BINDING OF CDK5 IN GLIOMA STEM CELLS USING SYNTHETIC INHIBITORS
  1230. Association of CDK5 and soluble oligomeric species of β-amyloid induced tau hyperphosphorylation
  1231. CDK5 influences the organization of the Circadian Machinery in peripheral clocks.
  1232. IN SILICO DESIGN OF QUERCETIN DERIVATIVES WITH POTENTIAL DUAL INHIBITORY ACTIVITY AGAINST GSK3β AND CDK5 /P25 FOR THE TREATMENT OF …
  1233. The loss of function of Cyclin-Dependent Kinase 5 (CDK5 ) alters the Cytoskeleton and decrease the in vitro Dengue Virus-2 infection
  1234. CDK5 Involvement in Cancer and in the Tumor Microenvironment
  1235. STEM-19. RESISTANCE IS FUTILE: UNDERSTANDING AND TARGETING THE CDK5 -CREB1-MCL1 AXIS TO PREVENT RADIATION RESISTANCE IN GLIOMA …
  1236. OGT/CDK5 /ACSS2 Axis Regulates Breast Cancer Brain Metastasis Growth.
  1237. The Role of CDK5 and TRPV1 in Meloxicam Resistance Signal Transduction in Rat Experiencing Chronic Pain.
  1238. CDK5 as a possible new target in biliary tract cancer: preliminary in-situ findings
  1239. Expression of CDK5 and its correlation with peripheral inflammation-related cells and prognosis in colon cancer patients
  1240. Studies on the regulatory mechanism of CHFR by neuronal CDK5 /p35
  1241. Investigation of Allosteric Inhibition Mechanisms by the Peptide P5 on the Alzheimer’s Disease (AD) Pathological Complex CDK5 -p25 through Molecular Dynamics …
  1242. CDK5 : A Mediator of Mptp Opening
  1243. Investigation of Allosteric Inhibition Mechanisms by the Peptide p5 on the Alzheimer’s Disease (AD) Pathological Complex CDK5 -p25 through Molecular …
  1244. CDK5 in RNA Biology: New Clues that may Underlie Neuronal and Glial Diseases
  1245. CDK5 promotes ventricular arrhythmogenesis through phosphorylation of N‐type calcium channels in cardiac sympathetic postganglionic neurons
  1246. Molecular Modeling Studies of Triazolyl Thiophenes As CDK5 /P25 inhHibitors Using 3D-QSAR and Molecular Docking
  1247. Understanding the Molecular Underpinnings of Neuronal Kinase CDK5 mediated Metabolic Vulnerabilities in Neuroendocrine Tumors
  1248. Parkinson´ s related protein DJ-1 is involved in aberrant cell cycle re-entry through CDK5
  1249. The role of oxidative stress in inhibiting FOXO1 through activating CDK5 in neuronal damage
  1250. Nutrient-Dependent Association of CDK5 Regulatory Associated Protein 1-Like 1 Gene with Insulin Secretion
  1251. Abstract LB-C04: Phosphoproteomics unravels dynamic regulation of energy sensor by CDK5 in Neuroendocrine Tumor
  1252. STEM-15. CDK5 AND NOTCH SIGNALING CROSSTALK DRIVES SELF-RENEWAL IN GSCs
  1253. Detailing the mechanism of CDK5 -mediated PD-L1 regulation in Medulloblastoma
  1254. VGLUT2/CDK5 /p25 Signaling Pathway Contributed to Inflammatory Pain By CFA
  1255. C34 INSIGHTS INTO COPD PATHOGENESIS FROM PRE-CLINICAL STUDIES: CDK5 Regulates Oxidative Stress In Cigarette Smoke Induced Apoptosis In …
  1256. D26 OXIDATIVE STRESS AND SIGNALING IN PULMONARY VASCULAR DISEASE: Hypoxia Induces CDK5 Mediated Phosphorylation And Upregulation Of Xanthine …
  1257. Systemic Administration of a Brain Permeable CDK5 Inhibitor Alters Neurobehavior
  1258. S-nitrosylation of CDK5 and its Activator p35 in Neuronal Morphogenesis and Synaptic Function
  1259. STEM-30. CDK5 INHIBITION RESOLVES PKA/cAMP-INDEPENDENT ACTIVATION OF CREB1 SIGNALING IN GLIOMA STEM CELLS
  1260. Functional roles of cyclin-dependent kinase 5 (CDK5 ) in embryonic neurogenesis
  1261. Erratum to: DDIS-27. TARGETING ATP DOCKING AND P35/P25 BINDING OF CDK5 IN GLIOMA STEM CELLS USING SYNTHETIC INHIBITORS
  1262. Expressions of CDK5 and p35/p25 in the blood of patients with vascular cognitive impairment
  1263. TNF-α increases production of reactive oxygen species through CDK5 activation in nociceptive neurons
  1264. Changes of CDK5 expression after focal brain contusion in rats
  1265. Effects of polydatin on learning and memory and CDK5 kinase activity in the hippocampus of rats with chronic alcoholism
  1266. Expressions of CDK5 and p35/p25 in the blood of patients with vascular cognitive impairment
  1267. Role of CDK5 in Activity-Induced Gene Expression and Dendrite Development
  1268. Erratum to: STEM-19. RESISTANCE IS FUTILE: UNDERSTANDING AND TARGETING THE CDK5 -CREB1-MCL1 AXIS TO PREVENT RADIATION RESISTANCE IN …
  1269. CDK5 downregulation enhances synaptic plasticity
  1270. CDK5 Substrate
  1271. Molecular Recognition of PPARγ by Kinase CDK5 /p25: Insights from a Combination of Proteinâ Protein Docking and Adaptive Biasing Force Simulations
  1272. P5-TAT: A Novel Medicine Targeting CDK5 Over-Activation for Radiation-Induced Brain Injury
  1273. Development of fluorescent biosensors and inhibitors to probe and target CDK5 /p25 in glioblastoma
  1274. Phosphorylation of synapsin I by CDK5 sets the ratio between the resting and recycling pools of synaptic vesicles at hippocampal synapses.
  1275. The role of CDK5 in the activation and effector function of T cells in experimental autoimmune uveitis (BA14P. 216)
  1276. RDNA-18. TP5, A PEPTIDE INHIBITOR OF ABERRANT AND HYPERACTIVE CDK5 /p25: A NOVEL THERAPEUTIC APPROACH AGAINST GLIOBLASTOMA
  1277. Understanding the Role of C yclin D ependent K inase 5 (CDK5 ) in Insulin Related Neurodegenerative Disease
  1278. Endothelial CDK5 deficit leads to the development of spontaneous epilepsy through CXCL1/CXCR2-mediated reactive astrogliosis
  1279. Sulfurous Heterocycles Based on the Transsulfuration Metabolite Lanthionine Ketimine Are Potent, Selective Antagonists of CDK5 /p25 Signaling with Broad Potential …
  1280. 890-P: CDK5 Regulatory Subunit-Associated Protein 1-Like 1 Promotes Adipocyte Proliferation through Transcriptional Activation of NEK8 in T2DM and Obesity
  1281. CDK5 controls IL-2 gene expression via repression of the mSin3a-HDAC complex (IRM6P. 719)
  1282. Effects of thin recipe of Buyang Huanwu decoction on CDK5 and apoptotic factors in an oxidative stress cell model
  1283. The role of oxidative stress in inhibiting FOXO1 through activating CDK5 in neuronal damage
  1284. Inhibition of roscovitine on the activity of CDK5 /p25 and phosphorylation of tau in retina of RCS rats after intravitreal injection
  1285. CDK5 -mediated Phosphorylation of Liprinα1 is Critical for Synaptic Plasticity
  1286. Progress in the study of new cancer target CDK5 and its inhibitors
  1287. AAV9-mediated CDK5 inhibitory peptide (CIP) reverses pathological changes and behavioral deficits in the Alzheimer’s disease model mice
  1288. CDK5 mediated coronin-1a phosphorylation is required for PLC-γ 1 mediated generation of inositol-1, 4, 5-trisphosphate and calcium mobilization after TCR activation …
  1289. Immunohistochemical Study of CDK5 and Ki-67 in Cervical Precancerous Lesion and Carcinoma
  1290. Expression pattern and diagnostic value of cyclin-dependent kinase 5 (CDK5 ) in colorectal tumors
  1291. Roles of CDK5 -dependent phosphorylation of liprinα1 in synaptic function and plasticity
  1292. CDK5 inhibition promotes neurogenesis while reducing self-renewal of brain tumor stem cells
  1293. AAV-9 Mediated CDK5 Inhibitory Peptide Protects Neurons in p25 and APP/PS1 Transgenic Mouse Models
  1294. CDK5 involves in interleukin-6 induces AR activation through phosphorylation of serine 727 Stat3 and serine 81 AR in prostate cancer cells
  1295. Role of CDK5 in the Pathogenesis of Cough Reflex Hypersensitivty in Guinea Pigs
  1296. Abstract A050: CDK5 disruption attenuates tumor PD-L1 expression via regulation of IFN-γ signaling components and promotes antitumor immunity
  1297. Role of CDK5 as a Tumor Suppressor Gene in Non-Small Cell Lung Cancer
  1298. A Wrinkle in CDK5 : A Necessary Gene for Cortical Folding
  1299. THE EFFECT OF DECREASED ACTIVITY IN THE FORM OF SPINAL CORD LIGATION ON CDK5 EXPRESSION IN SCIATIC NERVE AND BEHAVIORAL TEST OF …
  1300. Microtubule polarity in dendrites with CDK5 protein knock-down
  1301. The role of p35/CDK5 regulation by miR-15/107 family in Alzheimer’s disease
  1302. CDK5 -DA signaling has a key role in depressive like behaviours manifested at early disease stage in HD
  1303. The role of the CDK5 pathway and NMDA receptor phosphorylation in neurodegeneration in hippocampal sclerosis
  1304. The HU177 cryptic collagen epitope selectively regulates melanoma cell behavior by a CDK5 and PTPN12 associated mechanism
  1305. Abstract A30: Characterizing the non-linear dependency of the CDK5 -Rb axis in non-small cell lung cancer
  1306. Abstract A33: Biomarkers of CDK5 driven neuroendocrine tumors
  1307. CDK5 is Associated in Cardiac Calcium Channelopathy
  1308. Loss of CDK5 Function May Mediate Age‐Related Decline in Voluntary Physical Activity
  1309. Ubiquitin‐dependent and‐independent degradation of p35 activation subunit of neuronal Cdk, CDK5
  1310. A Novel Role of CDK5 in the Cell Cycle
  1311. Data Fabrication and Data Falsification in the paper entitled” Regulation of DARPP-32 dephosphorylation at PKA and CDK5 -sites by NMDA and AMPA receptors …
  1312. CDK5 opens the way for DLC1
  1313. Role of CDK5 -CRMP pathway in sevoflurane-induced dendritic develop-mental disorder of neurons in prefrontal cortex of neonatal rats
  1314. Deregulated CDK5 triggers multiple neuro-degenerative pathways in Alzheimer’s dis-ease models
  1315. Tnf-Alpha Increases CDK5 Activity Regulating Orofacial Pain Through Phosphorylation Of Trpv1 And P2x2 Ion Channels
  1316. CDK5 PLAYS A KEY ROLE IN PROLIFERATION, APOPTOSIS, AND IN VIVO TUMOR GROWTH OF DIFFUSE LARGE B-CELL LYMPHOMA
  1317. Inhibition of CDK5 /p25 by TFP5 protects dopaminergic neurons in MPTP-induced mouse model of Parkinson’s disease
  1318. CDK5 -mediated phosphorylation is required for the development and plasticity of dendritic spines
  1319. Effects of arsenic poisoning on neuronal cell apoptosis and mRNA and protein expression of calpain 1, calpain 2, and CDK5 /p25
  1320. Effects of Treadmill Exercise and Bright Light on Expression of GABAA receptor and CDK5 in Rat Hippocampus
  1321. Adhesion GPCR, Latrophilin-2 Induces Cardiac Differentiation Through CDK5 , Contributing to Repair After Myocardial Infarction
  1322. IP7K is kinetically well‐equipped for cell signaling but does not regulate CDK5 activity (1013.12)
  1323. APOE4 Induces Site-Specific Tau Phosphorylation Through Calpain-CDK5 Signaling Pathway in EFAD-Tg Mice.
  1324. The CDK inhibitor dinaciclib (SCH727965) inhibits the unfolded protein response (UPR) through a CDK1-and CDK5 -dependent mechanism
  1325. Human Neural Progenitor Cells are Productively Infected by R5-tropic HIV-1: Opiate Interactions on Infection and Function Involve CDK5 Signaling
  1326. CDK5 -dependent phosphorylation of liprinα1 mediates neuronal activity-dependent synapse development.
  1327. Molecular Recognition of PPAR# by the Kinase CDK5 /p25: Insights from a Combination of Protein-Protein Docking and Adaptive Biasing Force Simulations
  1328. Erratum: A numerical error in methodology section under Sequence retrieval and modeling side heading To: The role of CDK5 and GSK3B kinases in …
  1329. ERRATUM: CDK5 is essential for TGF-β1-induced epithelial-mesenchymal transition and breast cancer progression
  1330. CDK5 mediates activation of type I interferon pathway in PD
  1331. Post-transcriptional regulation of BDNF and the CDK5 pathway by the neuronal RNA binding protein HuD
  1332. To divide or differentiate?: nestin-mediated regulation of CDK5 in cell fate decisions
Related Posts

Medicinal Mushrooms

Diabetes & cancer

Nootropics

Mandatory FDA Disclaimer: Not intended to diagnose, treat, cure or prevent any disease.

Mandatory FDA Disclaimer: Not intended to diagnose, treat, cure or prevent any disease.

0
    0
    Your Cart
    Your cart is emptyReturn to Shop
    Continue Shopping